SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 6-K

 

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

 

For the month of May, 2022

Commission File Number 1565025

 


 

AMBEV S.A.

(Exact name of registrant as specified in its charter)

 

AMBEV S.A.

(Translation of Registrant's name into English)

 

Rua Dr. Renato Paes de Barros, 1017 - 3rd Floor
04530-000 São Paulo, SP
Federative Republic of Brazil

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 


Form 20-F ___X___ Form 40-F _______

 Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  

Yes _______ No ___X____

 

 
 

 

Ambev S.A.

Consolidated
interim financial statements at
March 31, 2022
and report on review

 

 
 

 

Report on review of consolidated
interim financial statements

 

 

To the Board of Directors and Shareholders

Ambev S.A.

 

 

 

 

Introduction

 

We have reviewed the accompanying consolidated interim balance sheet of Ambev S.A. and its subsidiaries ("Company") as at March 31, 2022 and the related consolidated statements of income, comprehensive income, changes in equity and cash flows for the quarter then ended, and notes, comprising significant accounting policies and other explanatory information.

 

Management is responsible for the preparation and fair presentation of these consolidated interim financial statements in accordance with the accounting standard International Accounting Standard (IAS) 34 - Interim Financial Reporting, of the International Accounting Standards Board (IASB). Our responsibility is to express a conclusion on these interim financial statements based on our review.

 

Scope of review

 

We conducted our review in accordance with International Standards on Reviews of Interim Financial Information (ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

 

Conclusion

 

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial statements referred to above do not present fairly, in all material respects, the financial position of Ambev S.A. and its subsidiaries as at March 31, 2022, and the consolidated financial performance and cash flows for the quarter then ended, in accordance with IAS 34.

 

 

São Paulo, May 18, 2022   

 

 

 

PricewaterhouseCoopers

Auditores Independentes Ltda.

CRC 2SP000160/O-5

 

 

 

Alessandro Marchesino de Oliveira

Contador CRC 1SP265450/O-8

 

 

 

 

 

AMBEV S.A.

 

 

CONTENTS

INTERIM CONSOLIDATED BALANCE SHEET 2
INTERIM CONSOLIDATED INCOME STATEMENT 4
INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 5
INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 6
INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS 8
1.   CORPORATE INFORMATION 9
2.   STATEMENT OF COMPLIANCE 11
3.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 12
4.   USE OF ESTIMATES AND JUDGMENTS 14
5.   CASH AND CASH EQUIVALENTS 15
6.   INVESTMENT SECURITIES 16
7.   INVENTORY 16
8.   RECOVERABLE TAXES 17
9.   DEFERRED INCOME TAX AND SOCIAL CONTRIBUTION 17
10.   PROPERTY, PLANT AND EQUIPMENT 20
11.   GOODWILL 23
12.   TRADE PAYABLES 24
13.   INTEREST-BEARING LOANS AND BORROWINGS 24
14.   PROVISIONS 25
15.   CHANGES IN EQUITY 28
16.   SEGMENT REPORTING 34
17.   NET SALES 37
18.   OTHER OPERATING INCOME/(EXPENSES) 37
19.   EXCEPTIONAL ITEMS 37
20.   FINANCE EXPENSES AND INCOME 38
21.   INCOME TAX AND SOCIAL CONTRIBUTION 38
22.   SHARE-BASED PAYMENTS 40
23.   FINANCIAL INSTRUMENTS AND RISKS 43
24.   COLLATERAL AND CONTRACTUAL COMMITMENTS WITH SUPPLIERS, ADVANCES FROM CUSTOMERS AND OTHERS 57
25.   CONTINGENCIES 58
26.   RELATED PARTIES 60

 

 

AMBEV S.A.

 

 

INTERIM CONSOLIDATED BALANCE SHEET

All amounts in thousands of Brazilian Reais unless otherwise stated

 

Assets Note 03/31/2022 12/31/2021
       
Cash and cash equivalents 5 12,887,922  16,627,698 
Investment securities 6 1,345,730  1,914,607 
Derivative financial instruments 23 624,271  597,392 
Trade receivable   4,383,951  4,791,634 
Inventories 7 11,426,297  11,000,346 
Income tax and social contributions recoverable   1,388,737  631,524 
Recoverable taxes 8 1,201,139  1,981,149 
Other assets   1,221,750  1,082,791 
Current assets   34,479,797  38,627,141 
       
       
Investment securities 6 206,949  192,877 
Derivative financial instruments 23 481  1,581 
Income tax and social contributions recoverable   5,819,918  6,326,908 
Recoverable taxes 8 6,068,835  6,005,396 
Deferred tax assets 9 4,090,340  4,727,749 
Other assets   2,014,472  2,063,265 
Employee benefits   22,983  27,850 
Investments in joint ventures   276,299  305,180 
Property, plant and equipment 10 27,494,375  29,224,261 
Intangible   7,732,029  8,689,015 
Goodwill 11 39,193,442  42,411,260 
Non-current assets   92,920,123  99,975,342 
       
Total assets   127,399,920  138,602,483 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements.

 

 

 

 

AMBEV S.A.

INTERIM CONSOLIDATED BALANCE SHEET (CONTINUED)

All amounts in thousands of Brazilian Reais unless otherwise stated

 

Equity and liabilities Note 03/31/2022 12/31/2021
       
Trade payables 12 21,954,834  25,077,911 
Derivative financial instruments 23 187,310  492,546 
Interest-bearing loans and borrowings 13 815,861  847,118 
Bank overdrafts 5 91,463  30,514 
Wages and salaries   1,553,475  2,439,448 
Dividends and interest on shareholders’ equity payable   1,293,733  1,425,045 
Income tax and social contribution payable   1,200,766  1,491,037 
Taxes and contributions payable   3,839,341  4,585,923 
Other liabilities   2,059,293  2,304,546 
Provisions 14 183,070  172,318 
Current liabilities   33,179,146  38,866,406 
       
Trade payables 12 558,414  617,056 
Interest-bearing loans and borrowings 13 2,170,483  2,253,406 
Deferred tax liabilities 9 2,940,481  3,213,967 
Income tax and social contribution payable   1,659,555  1,686,925 
Taxes and contributions payable   693,750  704,160 
Put option granted on subsidiaries and other liabilities   2,695,807  3,445,223 
Provisions 14 581,498  603,772 
Employee benefits   2,724,345  3,193,951 
Non-current liabilities   14,024,333  15,718,460 
       
Total liabilities   47,203,479  54,584,866 
       
Equity 15    
Issued capital   58,130,517  58,042,464 
Reserves   86,345,820  86,378,828 
Carrying value adjustments   (69,689,891) (61,778,261)
Retained earnings/(losses)   4,136,652 
Equity attributable to the equity holders of Ambev   78,923,098  82,643,031 
Non-controlling interests   1,273,343  1,374,586 
Total equity   80,196,441  84,017,617 
       
Total equity and liabilities   127,399,920  138,602,483 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements.

 

 

AMBEV S.A.

INTERIM CONSOLIDATED INCOME STATEMENT

For the period ended March 31

All amounts in thousands of Brazilian Reais unless otherwise stated

 

  Note 2022 2021
       
Net sales 17 18,439,152  16,639,761 
Cost of sales   (9,414,486) (7,945,330)
Gross profit   9,024,666  8,694,431 
       
Distribution expenses   (2,529,019) (2,129,593)
Sales and marketing expenses   (1,516,976) (1,445,040)
Administrative expenses   (1,173,436) (1,234,059)
Other operating income/(expenses), net 18 386,722  177,940 
Exceptional items 19 (27,226) (71,425)
Income from operations   4,164,731  3,992,254 
       
Finance expenses 20 (1,623,093) (1,444,395)
Finance income 20 1,026,380  380,095 
Net finance result   (596,713) (1,064,300)
       
Share of results of joint ventures   (2,404) (12,546)
Income before income tax   3,565,614  2,915,408 
       
Income tax expense 21 (36,776) (182,097)
Net income   3,528,838  2,733,311 
       
Attributable to:      
Equity holders of Ambev   3,412,772  2,625,412 
Non-controlling interest   116,066  107,899 
       
Basic earnings per share - common - R$   0.2168  0.1668 
Diluted earnings per share - common - R$   0.2153  0.1654 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements.

 

 

 

 

AMBEV S.A.

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the period ended March 31

All amounts in thousands of Brazilian Reais unless otherwise stated

 

  2022 2021
     
Net income 3,528,838  2,733,311 
     
Items that may be subsequently reclassified to profit or loss:    
Exchange differences on the translation of foreign operations (gains/(losses))    
Investment hedge - put option granted on subsidiaries 311,179  (163,002)
Gains/losses on translation of other foreign operations (7,309,774) 4,687,468 
Gains/losses on translation of foreign operations (6,998,595) 4,524,466 
     
Cash flow hedge - gains/(losses)    
Recognized in Equity (Hedge reserve) (685,748) 1,048,776 
Reclassified from Equity (Hedge reserve) and included in profit or loss (429,423) (391,456)
Total cash flow hedge (1,115,171) 657,320 
     
Items that will not be reclassified to profit or loss:    
Recognition of actuarial gains/(losses) 1,226  (56,151)
     
Other comprehensive (loss)/income (8,112,540) 5,125,635 
     
Total comprehensive income (4,583,702) 7,858,946 
     
Attributable to:    
   Equity holders of Ambev (4,496,599) 7,565,774 
   Non-controlling interest (87,103) 293,172 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements. The consolidated statement of comprehensive income is presented net of income tax. The income tax effects of these items are disclosed in Note 9 - Deferred income tax and social contribution.

 

 

AMBEV S.A.

 

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the period ended March 31

All amounts in thousands of Brazilian Reais unless otherwise stated

 

  Attributable to equity holders of Ambev      
  Capital Capital reserves Net income reserves Retained earnings Carrying value adjustments Total   Non-controlling interests Total equity
At January 1, 2021 57,899,073  54,985,511  25,920,061  (64,989,017) 73,815,628    1,335,496  75,151,124 
                   
 Net Income 2,625,412  2,625,412    107,899  2,733,311 
                   
Comprehensive income:                  
Gains/(losses) on the translation of foreign operations   4,340,712  4,340,712    183,754  4,524,466 
Cash flow hedges   655,880  655,880    1,440  657,320 
Actuarial gains/(losses)   (56,230) (56,230)   79  (56,151)
Total comprehensive income 2,625,412  4,940,362  7,565,774    293,172  7,858,946 
Capital increase (Note 15) 74,801  (74,333) 468    468 
Effect of application of IAS 29 (hyperinflation) 595,293  595,293    (1,236) 594,057 
Gains/(losses) of controlling interest 382  382    382 
Dividends paid   (41,160) (41,160)
Purchases of shares and results from treasury shares (32,061) (32,061)   (32,061)
Share-based payments 98,639  98,639    98,639 
At March 31, 2021 57,973,874  54,977,756  25,920,061  3,220,705  (60,048,273) 82,044,123    1,586,272  83,630,395 

 

 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements.

 

AMBEV S.A.

 

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the period ended March 31

All amounts in thousands of Brazilian Reais unless otherwise stated

 

  Attributable to equity holders of Ambev      
  Capital Capital reserves Net income reserves Retained earnings Carrying value adjustments Total   Non-controlling interests Total equity
At January 1, 2022 58,042,464  55,187,188  31,191,640  (61,778,261) 82,643,031    1,374,586  84,017,617 
                   
 Net Income 3,412,772  3,412,772    116,066  3,528,838 
                   
Comprehensive income:                  
Gains/(losses) on the translation of foreign operations (6,793,284) (6,793,284)   (205,311) (6,998,595)
Cash flow hedges (1,117,137) (1,117,137)   1,966  (1,115,171)
Actuarial gains/(losses) 1,050  1,050    176  1,226 
Total comprehensive income 3,412,772  (7,909,371) (4,496,599)   (87,103) (4,583,702)
Capital increase (Note 15) 88,053  (64,289) 23,764    23,764 
Effect of application of IAS 29 (hyperinflation) 723,880  723,880    2,081  725,961 
Gains/(losses) of controlling interest (2,259) (2,259)   (110) (2,369)
Dividends paid   (16,111) (16,111)
Purchases of shares and results from treasury shares 6,540  6,540    6,540 
Share-based payments 24,741  24,741    24,741 
At March 31, 2022 58,130,517  55,154,180  31,191,640  4,136,652  (69,689,891) 78,923,098    1,273,343  80,196,441 

 

 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements.

 

AMBEV S.A.

 

INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

For the period ended March 31

All amounts in thousands of Brazilian Reais unless otherwise stated

 

  Note 2022 2021
       
Net income   3,528,838  2,733,311 
Depreciation, amortization and impairment   1,330,963  1,263,530 
Impairment losses on receivables and inventory   72,104  27,251 
Additions/(reversals) in provisions and employee benefits   10,438  26,237 
Net finance costs 20 596,713  1,064,300 
Losses/(gains) on sale of property, plant and equipment and intangible assets   (33,423) (27,848)
Equity-settled share-based payment expenses 22 77,929  105,142 
Income tax expense 21 36,776  182,097 
Share of result of joint ventures   2,404  12,546 
Other non-cash items included in profit   (370,609) (427,211)
Cash flow from operating activities before changes in working capital and use of provisions   5,252,133  4,959,355 
       
(Increase)/decrease in trade and other receivables   857,142  1,464,781 
(Increase)/decrease in inventories   (1,252,106) (1,722,216)
Increase/(decrease) in trade and other payables   (2,637,607) (523,867)
Cash generated from operations   2,219,562  4,178,053 
       
Interest paid   (76,241) (56,234)
Interest received   119,532  54,250 
Dividends received   2,098  2,740 
Income tax paid   (1,745,195) (1,341,951)
Cash flow from operating activities   519,756  2,836,858 
       
Proceeds from sales of property, plant and equipment and intangible assets   37,271  39,744 
Proceeds from sales of subsidiaries' operations   382 
Acquisitions of property, plant and equipment and intangible assets   (888,537) (1,327,335)
Acquisitions of subsidiaries, net of cash acquired   (2,376) (89,036)
Acquisitions of other investments   (2,645)
Investments in short-term debt securities and net proceeds/(acquisitions) of debt securities   546,444  (349,075)
Net proceeds/(acquisitions) of other assets   5,044 
Cash flow from investing activities   (307,198) (1,722,921)
       
Capital increase   23,764  468 
Proceeds/(repurchases) of treasury shares   (7,791) (38,426)
Proceeds from borrowings   58,976  107,120 
Repayment of borrowings   (46,359) (434,663)
Cash net of finance costs other than interests   (2,560,803) 54,697 
Payment of lease liabilities   (165,401) (225,837)
Dividends and interest on shareholders' equity paid   (22,006) (1,241,110)
Cash flow from financing activities   (2,719,620) (1,777,751)
       
Net increase/(decrease) in cash and cash equivalents   (2,507,062) (663,814)
Cash and cash equivalents less bank overdrafts at the beginning of the year   16,597,184  17,090,335 
Effect of exchange rate fluctuations on cash and cash equivalents   (1,293,663) 859,547 
Cash and cash equivalents less bank overdrafts at the end of the year   12,796,459  17,286,068 

 

The accompanying notes are an integral part of these interim consolidated financial statements.


 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

1.CORPORATE INFORMATION

 

(a)Description of business

 

Ambev S.A. (referred to as the “Company” or “Ambev”) together with its subsidiaries (the “Group” or “Consolidated”), headquartered in São Paulo - SP, Brazil, has as its purpose, either directly or through participation in other companies, the production and sale of beer, draft beer, soft drinks, other non-alcoholic beverages, malt and food in general, as well as the advertising of its own and of third-party products; the sale of promotional and advertising materials; and the direct or indirect exploitation of bars, restaurants, snack bars and similar establishments, among others.

 

The Company’s shares and American Depositary Receipts (“ADRs”) are listed on the Brasil, Bolsa, Balcão S.A. (“B3”) under the ticker “ABEV3” and on the New York Stock Exchange (“NYSE”) under the ticker “ABEV”, respectively.

 

The Company’s direct controlling shareholders are Interbrew International B.V. (“ITW International”), AmBrew S.à.r.l (“Ambrew”), both of which are subsidiaries of Anheuser-Busch InBev N.V. (“AB InBev”), and Fundação Antonio e Helena Zerrenner Instituição Nacional de Beneficência (“Fundação Zerrenner”).

 

The interim financial statements were approved, in their final form, by the Board of Directors on May 04, 2022.

 

(b)Risks of climate change and the sustainability strategy

 

Considering the nature of the Company’s operations, there is an inherent exposure to certain risks related to climate change.

 

There was no significant change in the main risks considered by management related to those stated in the annual financial statements as of December 31, 2021.

 

(c)Major corporate events in 2022 and 2021

 

COVID-19 impacts

 

The outbreak of the novel coronavirus (SARS-CoV-2 or “COVID-19”) on a global scale has increased the volatility of the national and international markets, affecting the economies of the countries in which we operate and, consequently, the results of our operations. The response to the COVID-19 pandemic has evolved rapidly across the globe in a fluid and uncertain manner, including voluntary and, in some cases, mandatory quarantines, restrictions on travel, commercial and social activities, and ban on the distribution, sale and consumption of alcoholic beverages in some countries where we operate. Many of these measures have directly affected our sales, distribution and final consumer demand for our products.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

The impact of the pandemic on our operations and the restrictions imposed in response by national governments, especially since March 2020, have generated significant changes in market dynamics both in the off-trade sales channel, composed of supermarkets, and in the on-trade channel, which is composed of bars and restaurants. In countries with higher levels of income, more mature beer markets and a greater weighting towards the off-trade sales channel, such as Canada, the negative impact on the sales volume has been smaller. On the other hand, in countries with lower income levels and less mature beer markets, volume has been impacted according to the market segmentation between the on-trade and off-trade channels. In those cases, the reduction in volume is higher depending on the weighting of the on-trade channel. In all the cases, the more severe the restrictions on the sale and consumption of our products, the greater the reduction in volume, which is why Bolivia and Panama were among the worst-affected countries. On the other hand, we observed an increase in sales related to e-commerce in all countries, although this channel represents a small portion of the Company’s total volume.

In the beginning of the first quarter, our operations, especially in Brazil, were impacted by the wave of the COVID-19 variant Omicron which added to factors such as unfavorable climate, negatively impacted our sales. Through the remaining period, the consistency in the implementation of the Company’s strategy and the relaxation of restrictions in some regions, we observed a gradual increase in volumes across most of our operations, especially in Brazil, where there was a volume and net revenue increase related to the same period in 2021, mainly in March. However, there is still some uncertainty regarding the likelihood of new variants and likelihood of further government interventions or increase in restrictions, as well as the economic effects on financial markets and exchange rates. Those impacts may result in material adverse impacts on our business, liquidity, financial condition, and the outcome of operations. However, we are continuing to manage our liquidity and capital resources in a disciplined manner. Management have concluded that there are no substantial doubts regarding the Company’s ability to continue as a going concern.

As required by International Accounting Standard (“IAS”) 1 - Presentation of Financial Statements, the Company updated the analysis of the impact of COVID-19, as at March 31, 2022, which mainly involved, (i) a review of the assumptions of the annual impairment test, as described in Note 11 - Goodwill, (ii) an analysis of possible credit losses and inventory obsolescence, (iii) an analysis of the recoverability of deferred taxes, and (iv) the evaluation of the relevant estimates used for the preparation of the interim financial statements, among other analyses.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

Any impacts arising from these analyses are reflected in the interim financial statements and disclosed in explanatory notes. In addition, due to the protective actions taken for our staff and the donations made by our community, the Company incurred exceptional expenses of R$10,668, at March 31, 2022, as reported in Note 19 - Exceptional items.

 

Share buyback program

 

The Board of Directors, in a meeting held on March 18, 2021, approved, pursuant to article 30, Paragraph 1st, “b”, of Law 6,404/76 and Brazilian Securities and Exchange Commission (“CVM”) Instruction 567/15, a share buyback program of shares issued by the Company (“Program”) up to the limit of 5,700,000 common shares, with the primary purpose of covering any share delivery requirements contemplated in the Company’s share-based compensation plans or to be held in treasury, canceled and/or subsequently transferred. The Program will be in effect until September 18, 2022, as detailed in the Notice Regarding the Negotiation of Shares Issued by the Company, together with other information, in the form of Exhibit 30-XXXVI of CVM Instruction No. 480/09 as disclosed at March 18, 2021. The Company has 4,357,308,131 outstanding shares as defined in CVM Instruction 567/15. The acquisition was carried out in 2021, within the scope of the Program, as per a deduction of the capital reserve account recorded in the balance sheet dated as at December 31, 2020. The transaction was carried out, in 2021, through the following financial institutions: UBS Brasil Corretora de Câmbio, Títulos e Valores Mobiliários S.A. and Itaú Corretora de Valores S.A.

 

2.STATEMENT OF COMPLIANCE

 

The consolidated interim financial statements have been prepared using the going-concern accounting basis and are being presented in accordance with IAS 34 - Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”).

 

The information does not meet all disclosure requirements for the presentation of full annual financial statements and thus should be read in conjunction with the consolidated financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) for the year ended December 31, 2021. To avoid duplication of disclosures which are included in the annual financial statements, the following notes were not subject to full filling:

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

(a)Summary of significant accounting policies (Note 3);
(b)Trade receivables (Note 20);
(c)Investment securities (Note 16);
(d)Intangibles (Note 15);
(e)Goodwill (Note 14);
(f)Interest-bearing loans and borrowings (Note 23);
(g)Employee benefits (Note 24);
(h)Changes in equity (Note 22);
(i)Additional information on operating expenses by nature (Note 10);
(j)Payroll and related benefits (Note 09);
(k)Contingencies (Note 30);
(l)Group companies (Note 33); and
(m)Insurance (Note 34).

 

3.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

There were no significant changes in the accounting policies and calculation methods used for the interim financial statements as at March 31, 2022 compared to those presented in the financial statements for the years ended December 31, 2021.

 

(a)Basis of preparation and measurement

The interim financial statements are presented in thousands of Brazilian Reais (“R$”), unless otherwise indicated, rounded to the nearest thousand. The measurement basis used in preparing the interim financial statements is the historical cost, net realizable value, fair value or recoverable amount.

(b)Recently issued IFRS

 

There were no new standards for the period ended March 31, 2022 for the preparation of these interim financial statements.

Other Standards, Interpretations and Amendments to Standards

 

There are no other Standards, Interpretations and/or Amendments to Standards that are not in force and that the Company expects to have a material impact resulting from their application in the interim consolidated financial statements on the entity in the current or future reporting periods, or on foreseeable future transactions.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

(c)Foreign currency conversion

 

Exchange rates

 

The main exchange rates used in the preparation of the Company’s interim financial statements are as follows:

 

      Closing rate   Average rate
Currency Name Country 03/31/2022 12/31/2021   03/31/2022 03/31/2021
               
CAD Canadian Dollar Canada 3.7848  4.3914    4.2043  4.2960 
DOP Dominican Peso Dominican Republic 0.0859  0.0970    0.0944  0.0938 
USD US Dollar Panamá and Cuba (i) 4.7378  5.5805    5.3549  5.3687 
GTQ Quetzal Guatemala 0.6182  0.7201    0.6915  0.6954 
ARS Argentinean Peso Argentina 0.0427  0.0543    0.0511  0.0568 
BOB Bolivian Peso Bolivia 0.6807  0.8018    0.7694  0.7714 
PYG Guarani Paraguay 0.0007  0.0008    0.0008  0.0008 
UYU Uruguayan Peso Uruguay 0.1152  0.1249    0.1224  0.1236 
CLP Chilean Peso Chile 0.0060  0.0066    0.0065  0.0071 
BBD Barbadian Dollar Barbados 2.3355  2.7510    2.6397  2.6465 

 

(i) The functional currency of Cuba has parity with the US dollar (“USD”) on the financial statement date.

 

4.USE OF ESTIMATES AND JUDGMENTS

 

The preparation of interim financial statements in compliance with IFRS requires Management to make use of judgments, estimates and assumptions that affect the application of accounting practices and the reported amounts of assets and liabilities, income and expenses. The estimates and assumptions are based on past experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for decision-making regarding judgments regarding the carrying amounts of assets and liabilities that are not readily evident from other sources. The actual results may differ from these estimates.

The estimates and assumptions are reviewed on a regular basis. Changes in accounting estimates may affect the period during which they are realized, or future periods.

Although each significant accounting policy reflects judgments, assessments or estimates, the Company believes that the following accounting practices reflect the most critical judgments, estimates and assumptions that are important to its business operations and the understanding of its results:

(i) Predecessor basis of accounting;

(ii) Business combinations;

(iii) Impairment;

(iv) Provisions, including tax contingencies;

(v) Share-based payments;

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

(vi) Employee benefits;

(vii) Current and deferred tax;

(viii) Joint arrangements;

(ix) Measurement of financial instruments, including derivatives;

(x) Assets and liabilities recognition related to extemporaneous tax credits and debits;

(xi) Accounting and financial reporting in hyperinflationary economies; and

(xii) Leases.

 

The fair values of acquired identifiable intangibles with indefinite useful lives are based on an assessment of future cash flow. Impairment analyses of goodwill and intangible assets with indefinite useful lives are performed at least annually, or whenever a triggering event occurs, to determine whether the carrying value exceeds the recoverable amount.

 

The Company uses its judgment to choose between a variety of methods including the net fair value of expenses approach and option valuation models and makes assumptions about the fair value of financial instruments mainly based on the market conditions at each balance sheet date.

 

Actuarial assumptions regarding future events are used for the calculation of projected pension and other long-term employee benefit expenses and liabilities. These factors include assumptions regarding interest rates, rates of increase in healthcare costs, rates of future compensation increases, turnover rates, and life expectancy. Such estimates are reviewed annually by independent actuaries.

 

The Company is subject to income tax in numerous jurisdictions. Significant judgment is required to determine the Company’s worldwide provision for income tax. There are some transactions and calculations for which the ultimate tax determination is uncertain. Some of the subsidiaries of the Company are involved in tax audits, usually in relation to prior years. These audits are ongoing in various jurisdictions as at the balance sheet date, and by their nature, can take a considerable time to complete.

 

To measure the amounts of extemporaneous tax credits arising from lawsuits, the Company evaluates the documents for the period covered by the lawsuit, and applies the guidelines for the final decision, applicable legislation or other elements that enable the amount to be estimated with sufficient reliability.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

5.       CASH AND CASH EQUIVALENTS

 

  03/31/2022 12/31/2021
     
Cash 259,819  651,160 
Current bank accounts 4,818,822  4,582,937 
Short-term bank deposits (i) 7,809,281  11,393,601 
Cash and cash equivalents 12,887,922  16,627,698 
     
Bank overdrafts (91,463) (30,514)
Cash and cash equivalents less bank overdraft 12,796,459  16,597,184 

 

(i) The balance refers mostly to Bank Deposit Certificates (“CDBs”), of high liquidity, which are readily convertible into known amounts of cash and which are subject to an insignificant risk of change in value.

 

The cash and cash equivalents balance include the amount of R$1,022 million as at March 31, 2022 (R$975 million in 2021) held in Cuba and Argentina, which is not freely transferable to the parent company due to remittance restrictions.

 

6.       INVESTMENT SECURITIES

 

  03/31/2022 12/31/2021
     
Financial assets at fair value through profit or loss 1,345,730  1,914,607 
Current investment securities 1,345,730  1,914,607 
     
Investment on debt securities (i) 206,949  192,877 
Non-current investment securities 206,949  192,877 
     
Total 1,552,679  2,107,484 

 

(i) The balance refers substantially to Bank Deposit Certificates (“CDBs”) which are linked to tax incentives and do not have immediate convertibility into a known amount of cash.

 

7.       INVENTORY

 

  03/31/2022 12/31/2021
     
Finished goods 3,921,562  3,626,651 
Work in progress 796,218  672,542 
Raw materials and consumables 5,429,155  5,306,223 
Spare parts and others 865,139  906,805 
Prepayments 533,432  645,899 
Impairment losses (119,209) (157,774)
  11,426,297  11,000,346 

 

The changes in impairment losses on inventory are as follows:

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

At December 31, 2020 (141,148)
Effects of movements in foreign exchange in the balance sheet (2,015)
Provisions (191,575)
Write-off 176,964 
At December 31, 2021 (157,774)
Effects of movements in foreign exchange in the balance sheet 16,553 
Provisions (53,740)
Write-off 75,752 
At March 31, 2022 (119,209)

 

8.       RECOVERABLE TAXES

  03/31/2022 12/31/2021
PIS/COFINS exclusion of ICMS (i) 28,627  516,982 
PIS/COFINS 367,969  648,587 
ICMS 585,466  565,551 
IPI 168,128  168,584 
Other 50,949  81,445 
Current 1,201,139  1,981,149 
     
PIS/COFINS exclusion of ICMS (i) 5,438,874  5,360,021 
ICMS 377,030  383,617 
Other 252,931  261,758 
Non-current 6,068,835  6,005,396 
     
Total 7,269,974  7,986,545 

 

(i) As detailed in Note 25 - Contingencies, the Company recognized PIS and COFINS credits arising from the exclusion of ICMS from the calculation basis. The corresponding entry for recognition is recorded in the item Recoverable PIS/COFINS - exclusion of ICMS, according to the table above.

9.DEFERRED INCOME TAX AND SOCIAL CONTRIBUTION

 

Deferred taxes for income tax and social contribution taxes are calculated on temporary differences between the tax bases of these taxes and the accounting calculations of the Company, which include tax losses. The tax rates in Brazil, which are expected to be applicable upon the realization of the deferred taxes, are 25% for income tax and 9% for social contribution. For other regions in which the Company operates, the expected nominal rates are as follow:

 

Central America and the Caribbean from 15% to 27%
Latin America - South (i) from 10% to 35%
Canada 26.5%

 

(i) Amendments to Argentine tax legislation enacted in June, 2021 and applicable from January, 2021 increased the income tax rate from 30% to 35%.

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

Deferred tax assets are recognized to the extent that it is probable that future taxable profits are probable, which may be offset against recorded temporary differences at March 31, 2022.

 

The amount of deferred income tax and social contribution by type of temporary difference is detailed as follows:

 

  03/31/2022   12/31/2021
  Assets Liabilities Net   Assets Liabilities Net
Investment securities 11,958  (3,404) 8,554    12,535  (2,451) 10,084 
Intangible (1,448,244) (1,448,244)   (1,634,450) (1,634,450)
Employee benefits 907,412  (606) 906,806    1,278,221  (1,953) 1,276,268 
Trade payables 3,056,758  (2,052) 3,054,706    4,113,285  (1,104) 4,112,181 
Trade receivable 53,047  53,047    50,583  50,583 
Derivatives 177,087  (111,538) 65,549    232,159  (72,381) 159,778 
Interest-bearing loans and borrowings (1,294) (1,294)   (1,646) (1,646)
Inventories 273,478  (78,691) 194,787    328,187  (49,136) 279,051 
Property, plant and equipment 586,559  (1,869,208) (1,282,649)   645,372  (2,026,973) (1,381,601)
Withholding tax on undistributed profits and royalties 87,625  (1,514,132) (1,426,507)   (2,079,452) (2,079,452)
Investments in joint ventures (421,589) (421,589)   (421,589) (421,589)
Interest on shareholders' equity 746,607  746,607   
Losses carried forward 1,302,966  1,302,966    1,298,807  1,298,807 
Provisions 645,565  (3,726) 641,839    696,879  (217) 696,662 
Complement of income tax of foreign subsidiaries due in Brazil (7,090) (7,090)  
Impact of the adoption of IFRS 16 (Leases) 70,760  (391) 70,369    78,610  (343) 78,267 
ICMS on the assessment bases of PIS/COFINS (1,019,595) (1,019,595)   (1,019,608) (1,019,608)
Other items 100,833  (389,236) (288,403)   110,417  (19,970) 90,447 
Gross deferred tax assets/(liabilities) 8,020,655  (6,870,796) 1,149,859    8,845,055  (7,331,273) 1,513,782 
Netting by taxable entity (3,930,315) 3,930,315    (4,117,306) 4,117,306 
Net deferred tax assets/(liabilities) 4,090,340  (2,940,481) 1,149,859    4,727,749  (3,213,967) 1,513,782 

 

The Company only reclassifies the balances of deferred income tax and social contribution assets against liabilities to a net presentation basis when the applicable compensation criteria are met.

The critical estimates of Ambev’s Management, as well the main contingencies related to uncertainty about the tax treatment of income, are disclosed in Notes 4 (i) and 25, respectively.

 

As at March 31, 2022 the deferred tax assets and liabilities related to combined tax losses which are expected to be utilized or settled using temporary differences, as follows:

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

  03/31/2022
Deferred taxes not related to tax losses to be realized until 12 months to be realized after 12 months Total
       
Investment securities 8,554  8,554 
Intangible (1,281) (1,446,963) (1,448,244)
Employee benefits 83,922  822,884  906,806 
Trade payables (208,888) 3,263,594  3,054,706 
Trade receivable 42,112  10,935  53,047 
Derivatives (178,555) 244,104  65,549 
Interest-bearing loans and borrowings (1,294) (1,294)
Inventories 230,842  (36,055) 194,787 
Property, plant and equipment 9,063  (1,291,712) (1,282,649)
Withholding tax on undistributed profits and royalties (91,403) (1,335,104) (1,426,507)
Investments in joint ventures (421,589) (421,589)
Interest on shareholders' equity 746,607  746,607 
Provisions 327,281  314,558  641,839 
Complement of income tax of foreign subsidiaries due in Brazil (7,090) (7,090)
Impact of the adoption of IFRS 16 (Leases) 45  70,324  70,369 
ICMS on the assessment bases of PIS/COFINS (1,019,595) (1,019,595)
Other items 90,221  (378,624) (288,403)
Total 1,041,582  (1,194,689) (153,107)

 

The majority of tax losses and negative social contribution bases on which deferred income tax and social contribution were calculated do not have a statute of limitations. The use of credits related to tax losses is based on the projected future existence of taxable profits, limited to 30% of taxable income for the year, according to the actual figures for prior years, and the projections of the Company’s business in the economies in which it is located, and thus is in compliance with the applicable fiscal and accounting rules.

 

Deferred tax related to tax losses 03/31/2022
2022 178,700 
2023 223,234 
2024 111,433 
2025 230,320 
2026 to 2028 119,613 
2029 to 2030 383,719 
2030 to 2031 (i) 55,947 
Total 1,302,966 

 

(i) There is no expectation of realization beyond a term of ten years.

 

As at March 31, 2022, the tax credits related to tax losses in the amount of R$898,482 (R$1,055,557 in 2021) were not recorded, as realization is not probable.

 

A significant portion of the deferred tax assets related to the tax losses amount do not have any limits on carrying forward or utilization, and the tax losses carried forward in relation to credit are equivalent to R$3,488,396 at March 31, 2022 (R$4,122,454 in December 31, 2021).

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

The net change in deferred income tax and social contribution is detailed as follows:

 

At December 31, 2021 1,513,782 
Recognition of actuarial gains/(losses) 23 
Investment hedge - put option granted on subsidiaries (160,304)
Cash flow hedge - gains/(losses) 359,257 
Gains/(losses) on translation of other foreign operations (652,776)
Recognized in other comprehensive income (453,800)
Recognized in the income statement 225,600 
Changes directly in the balance sheet (135,723)
Recognized in deferred tax (136,741)
Effect of application of IAS 29 (hyperinflation) (136,741)
Recognized in other balance sheet group 1,018 
At March 31, 2022 1,149,859 

 

10.    PROPERTY, PLANT AND EQUIPMENT

 

  03/31/2022 12/31/2021
Property, plant and equipment 25,003,039  26,664,070 
Right of use assets 2,491,336  2,560,191 
  27,494,375  29,224,261 

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

 

  Land and buildings Plant and equipment Fixtures and fittings Under construction Total
Acquisition cost          
At December 31, 2020 12,385,108  34,037,311  7,219,152  2,830,543  56,472,114 
Effects of movements in foreign exchange in the balance sheet 54,109  128,963  4,295  6,031  193,398 
Effects of application of IAS 29 (hyperinflation) 544,167  1,170,073  216,392  148,722  2,079,354 
Acquisition through business combinations 859  8,558  549  1,134  11,100 
Acquisitions 11,291  960,138  45,213  6,294,391  7,311,033 
Disposals and write-offs (117,681) (1,238,356) (360,415) (3,382) (1,719,834)
Transfers to other asset categories 662,036  2,402,864  401,544  (3,872,918) (406,474)
At December 31, 2021 13,539,889  37,469,551  7,526,730  5,404,521  63,940,691 
Effects of movements in foreign exchange in the balance sheet (900,575) (2,685,177) (657,301) (277,280) (4,520,333)
Effects of application of IAS 29 (hyperinflation) 204,084  655,859  171,261  49,850  1,081,054 
Acquisitions 113  200,146  7,619  661,713  869,591 
Disposals and write-offs (27) (204,784) (139,967) (344,778)
Transfers to other asset categories 230,780  742,389  112,038  (1,130,560) (45,353)
At March 31, 2022 13,074,264  36,177,984  7,020,380  4,708,244  60,980,872 
           
  Land and buildings Plant and equipment Fixtures and fittings Under construction Total
Depreciation          
At December 31, 2020 (3,993,438) (23,830,425) (5,795,390) (33,619,253)
Effects of movements in foreign exchange in the balance sheet (39,654) (52,366) 10,586  (81,434)
Effects of application of IAS 29 (hyperinflation) (94,101) (557,581) (146,594) (798,276)
Acquisition through business combinations (258) (1,065) (196) (1,519)
Depreciation (398,116) (3,098,465) (634,431) (4,131,012)
Disposals and write-offs 46,584  1,222,553  320,579  1,589,716 
Transfers to other asset categories 36,617  1,303  5,398  43,318 
Others (7,115) (268,996) (2,050) (278,161)
At December 31, 2021 (4,449,481) (26,585,042) (6,242,098) (37,276,621)
Effects of movements in foreign exchange in the balance sheet 221,891  1,842,155  561,842  2,625,888 
Effects of application of IAS 29 (hyperinflation) (37,874) (430,529) (154,127) (622,530)
Depreciation (102,701) (760,228) (145,553) (1,008,482)
Disposals and write-offs 207,921  132,389  340,310 
Transfers to other asset categories 9,350  11,975  1,175  22,500 
Others 223  (59,121) (58,898)
At March 31, 2022 (4,358,592) (25,772,869) (5,846,372) (35,977,833)
           
Carrying amount:          
At December 31, 2021 9,090,408  10,884,509  1,284,632  5,404,521  26,664,070 
At March 31, 2022 8,715,672  10,405,115  1,174,008  4,708,244  25,003,039 

 

The balances of fixed assets provided as security are not material.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

Right-of-use assets:

 

  Buildings Machinery, equipment and vehicles Others Total
Acquisition cost        
At December 31, 2020 1,791,518  1,905,890  175,541  3,872,949 
Effects of movements in foreign exchange in the balance sheet 51,838  6,659  3,556  62,053 
Additions 803,868  1,419,365  61,411  2,284,644 
Write-offs (312,351) (1,327,771) (122,748) (1,762,870)
Transfers from (to) other asset categories (27,692) 19,747  (6,055) (14,000)
At December 31, 2021 2,307,181  2,023,890  111,705  4,442,776 
Effects of movements in foreign exchange in the balance sheet (135,053) (16,728) (7,119) (158,900)
Additions 83,690  170,656  5,290  259,636 
Write-offs (392) (82,670) (83,062)
Transfers from (to) other asset categories (25,384) 17,152  (336) (8,568)
At March 31, 2022 2,230,042  2,112,300  109,540  4,451,882 
         
  Buildings Machinery, equipment and vehicles Others Total
Depreciation        
At December 31, 2020 (812,874) (1,017,907) (126,674) (1,957,455)
Effects of movements in foreign exchange in the balance sheet (19,328) (2,840) (2,265) (24,433)
Depreciation (476,324) (497,286) (50,782) (1,024,392)
Write-offs 205,790  794,893  109,604  1,110,287 
Transfers (from) to other asset categories 1,537  (1,043) 12,914  13,408 
At December 31, 2021 (1,101,199) (724,183) (57,203) (1,882,585)
Effects of movements in foreign exchange in the balance sheet 59,537  7,095  3,650  70,282 
Depreciation (72,970) (89,383) (8,888) (171,241)
Write-offs 129  6,520  6,649 
Transfers (from) to other asset categories 2,721  10,270  3,358  16,349 
At March 31, 2022 (1,111,782) (789,681) (59,083) (1,960,546)
         
Carrying amount:        
At December 31, 2021 1,205,982  1,299,707  54,502  2,560,191 
At March 31, 2022 1,118,260  1,322,619  50,457  2,491,336 

 

Term contracts and discount rate

The Company estimated discount rates, based on risk-free interest rates observed in the Brazilian market, for the terms of its contracts, adjusted to their reality (credit spread). Spreads were obtained with financial institutions. The following table shows the rates applied:

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

  Rate %
Lease Term 03/31/2022 12/31/2021
2021-2025 7.46% 7.29%
2026-2030 9.47% 9.78%
2031-2035 13.22% 14.47%

 

 

11.GOODWILL

 

  03/31/2022 12/31/2021
     
Balance at the end of the previous year 42,411,260  40,023,457 
Effects of movements in foreign exchange in the balance sheet (3,609,412) 1,255,314 
Effect of application of IAS 29 (hyperinflation) 391,594  1,092,437 
Acquisitions, (write-offs) and disposal through business combinations 40,052 
Balance at the end of the year 39,193,442  42,411,260 

 

The carrying amount of goodwill was allocated to the different cash-generating units as follows:

 

  Functional currency 03/31/2022 12/31/2021
       
Brazil BRL 17,702,415  17,702,415 
Goodwill   102,945,048  102,945,048 
 Non-controlling transactions (i)   (85,242,633) (85,242,633)
       
CAC:      
Dominican Republic DOP 3,928,809  4,439,344 
Panama PAB 1,646,931  1,939,896 
       
Latin America - South:      
Argentina ARS 2,778,297  3,232,649 
Bolivia BOB 1,675,858  1,973,945 
Chile CLP 52,613  57,371 
Paraguay PYG 1,069,702  1,083,196 
Uruguay UYU 170,897  185,166 
       
Canada CAD 10,167,920  11,797,278 
    39,193,442  42,411,260 

 

(i) This refers to the shareholding exchange transaction in 2013 as a result of the adoption of the predecessor basis of accounting.

 

Impairment testing

The impairment test is updated annually considering the most accurate estimates calculated by management. For the second year of the model, we used the assumptions that were already considered for the projection of the other years, considering that they are still valid. There are no indications of impairment until March 31, 2022.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

12.TRADE PAYABLES

 

  03/31/2022 12/31/2021
     
Trade payables (i) 20,847,248  23,867,688 
Related parties (Note 26) 1,107,586  1,210,223 
Current 21,954,834  25,077,911 
     
Trade payables (i) 215,238  209,140 
Related parties (Note 26) 343,176  407,916 
Non-current 558,414  617,056 
     
Total 22,513,248  25,694,967 

 

(i) The nominal contractual amounts, including interest, amount to R$23,527 million at March 31, 2022 (R$29,103 million at December 31, 2021). 

 

 

 

13.    INTEREST-BEARING LOANS AND BORROWINGS

 

  03/31/2022 12/31/2021
     
Secured bank loans 66,513  72,760 
Unsecured bank loans 85,782  84,070 
Other unsecured loans 36,338  37,250 
Lease liabilities 627,228  653,038 
Current liabilities 815,861  847,118 
     
Secured bank loans 152,341  174,279 
Other unsecured loans 94,491  92,858 
Lease liabilities 1,923,651  1,986,269 
Non-current liabilities 2,170,483  2,253,406 

 

Additional information regarding the exposure of the Company to interest rate risk, foreign currency risk and debt repayment schedule risk are disclosed in Note 23 - Financial instruments and risks.

 

Contractual clauses (Covenants)

 

As at March 31, 2022, the Company’s loans had equal rights to payment without subordination clauses. For the credit lines due to FINAME contracted by the Company with Banco Nacional de Desenvolvimento Econômico e Social (“BNDES”), the assets acquired using the credit granted were placed as collateral. Other loans and financing contracted by the Company require only personal guarantees as collateral, or are unsecured. Most loan contracts contain contractual covenants, including: financial covenants, including limitations on new indebtedness; going-concern basis; maintenance, in use or in good condition for the business, of the Company’s assets; restrictions on acquisitions, mergers, sales or disposals of its assets; disclosure of financial statements and the balance sheet; no prohibitions related to new guarantees for loans contracted, except if: (i) expressly authorized under the agreement; (ii) new loans contracted from financial institutions linked to the Brazilian government including BNDES or foreign governments; or foreign governments, multilateral financial institutions (e.g. the World Bank) or in jurisdictions in which the Company operates.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

Additionally, all agreements with BNDES are subject to certain “provisions applicable to agreements entered into with BNDES” (“Provisions”). Such Provisions require the borrower to obtain prior consent from BNDES if they, for instance, wish to: (i) raise new loans (except for the loans described in the Provisions); (ii) give preference and/or priority to other debts; and/or (iii) dispose of or encumber any items of their fixed assets (except as provided for within the Provisions).

These clauses are applicable from the date of execution and effectiveness of each contract, to the extent that the events mentioned in the contract occur. Depending on the materiality of each event and its potential adverse effects on the Company and /or its subsidiaries or the rights of its creditors, contractual penalties may be applied, including the early maturity of the respective contract. In certain contracts, in the event of occurrence of any of the events set out in the restrictive clauses, the Company may be granted a grace period to resolve any contractual defaults, in order to avoid any penalties resulting from the breach of its obligations.

As at March 31, 2022, the Company was in compliance with all of its contractual obligations for its loans and financing.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

14.    PROVISIONS

 

(a) Provision changes

 

  Balance as at December 31, 2020 Effect of changes in foreign exchange rates Additions Provisions used Provisions reversed Balance as at December 31, 2021
             
Provision for disputes and litigation            
Taxes on sales 184,196  198,519  (57,308) (106,854) 218,553 
Labor 129,842  (820) 163,142  (147,167) (20,809) 124,188 
Civil 86,856  (2,207) 273,888  (71,838) (33,745) 252,954 
Other taxes 156,612  2,000  14,562  (5,159) (5,026) 162,989 
Total provision for disputes and litigation 557,506  (1,027) 650,111  (281,472) (166,434) 758,684 
             
Restructuring 14,492  1,153  6,796  (5,035) 17,406 
             
Total provisions 571,998  126  656,907  (286,507) (166,434) 776,090 

 

 

  Balance as at December 31, 2021 Effect of changes in foreign exchange rates Additions Provisions used Provisions reversed Balance as at March 31, 2022
             
Provision for disputes and litigation            
Taxes on sales 218,553  24,985  (12,944) (834) 229,760 
Labor 124,188  (2,726) 35,743  (28,108) (3,478) 125,619 
Civil 252,954  (8,250) 13,265  (1,826) (11,811) 244,332 
Other taxes 162,989  (10,110) 494  (457) (273) 152,643 
Total provision for disputes and litigation 758,684  (21,086) 74,487  (43,335) (16,396) 752,354 
             
Restructuring 17,406  (2,093) (3,099) 12,214 
             
Total provisions 776,090  (23,179) 74,487  (46,434) (16,396) 764,568 
 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

(b)Expected settlement

 

    03/31/2022     12/31/2021
  Current Non-current   Current Non-current
           
Provision for disputes and litigation          
Taxes on sales 62,355  167,405    55,390  163,163 
Labor 30,370  95,249    27,967  96,221 
Civil 62,699  181,633    58,835  194,119 
Other taxes 22,502  130,141    20,922  142,067 
Total provision for disputes and litigation 177,926  574,428    163,114  595,570 
           
Restructuring 5,144  7,070    9,204  8,202 
           
Total provisions 183,070  581,498    172,318  603,772 

 

The expected settlement of provisions was based on management’s best estimate at the balance sheet date.

(c) Main lawsuits with a probable likelihood of loss:

(c.1) Sales taxes

 

In Brazil, the Company and its subsidiaries are parties to various administrative and judicial proceedings related to ICMS, IPI, PIS and COFINS taxes. Such proceedings include, among others, tax offsetting, appropriation of tax credits and alleged insufficient payment of the respective taxes.

 

(c.2) Labor

The Company and its subsidiaries are parties to labor proceedings with former employees or former employees of service providers. The main issues involve overtime and related effects and respective charges.

 

(c.3) Civil

The Company is involved in civil lawsuits considered as representing a probable likelihood of loss. The most relevant portion of these lawsuits refers to former distributors, mainly in Brazil, mostly claiming damages resulting from the termination of their contracts.

 

The processes representing possible probabilities are disclosed in Note 25 - Contingencies.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

15.    CHANGES IN EQUITY

 

(a) Capital stock

 

    03/31/2022     03/31/2021
  Thousands  of common shares Thousands  of Real   Thousands  of common shares Thousands  of Real
Beginning balance 15,744,452  58,042,464    15,735,118  57,899,073 
Capital increase (i) 5,765  88,053    4,125  74,801 
Final balance (ii) 15,750,217  58,130,517    15,739,243  57,973,874 

 

(i) Capital increase related to the issue of shares.

 

(ii) The capital stock is fully subscribed and paid up.

 

(b) Capital reserves

 

  Capital Reserves  
  Treasury shares Share Premium Other capital reserves Share-based Payments  Total
At January 1, 2021 (941,637) 53,662,811  700,898  1,563,439  54,985,511 
Capital increase (74,333) (74,333)
Purchases of shares and results from treasury shares (32,061) (32,061)
Share-based payments 98,639  98,639 
At March 31, 2021 (973,698) 53,662,811  700,898  1,587,745  54,977,756 

 

 

  Capital Reserves  
  Treasury shares Share Premium Other capital reserves Share-based Payments  Total
At January 1, 2022 (1,037,711) 53,662,811  700,898  1,861,190  55,187,188 
Capital increase (64,289) (64,289)
Purchases of shares and results from treasury shares 6,540  6,540 
Share-based payments 24,741  24,741 
At March 31, 2022 (1,031,171) 53,662,811  700,898  1,821,642  55,154,180 

 

(b.1) Purchase of shares and result of treasury shares

 

Treasury shares represent the Company’s own issued shares reacquired by the Company, and the results of treasury shares related to gains and losses on share-based payment transactions and others.

The changes in treasury shares are as follow:

 

  Acquisition/realization of shares   Result on Treasury Shares   Total Treasury Shares
  Thousands of  shares   Thousands of  Brazilian Reais   Thousands of shares   Thousands of Brazilian Reais
At January 1, 2021 203    (3,045)   (938,592)   (941,637)
Changes during the year 2,027    (31,372)   (689)   (32,061)
At March 31, 2021 2,230    (34,417)   (939,281)   (973,698)
 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

 

  Acquisition/realization of shares   Result on Treasury Shares   Total Treasury Shares
  Thousands of  shares   Thousands of  Brazilian Reais   Thousands of shares   Thousands of Brazilian Reais
At January 1, 2022 5,783    (98,140)   (939,571)   (1,037,711)
Changes during the year (452)   8,606    (2,066)   6,540 
At March 31, 2022 5,331    (89,534)   (941,637)   (1,031,171)

 

(b.2) Share premium

 

The share premium refers to the difference between the subscription price that the shareholders paid for the shares and their nominal value. Since this is a capital reserve, it can only be used to increase capital, offset losses, or redeem, reimburse or repurchase shares.

(b.3) Share-based payment

Different share-based payment programs and stock purchase option plans allow the senior management from Ambev’s economic group to acquire shares in the Company.

The share-based payment reserve recorded a charge of R$77,929 on March 31, 2022 (R$105,142 at March 31, 2021) (Note 22 - Share-based payments).

 

(c) Net income reserves

 

  Net income reserves
  Investments reserve  Legal reserve  Fiscal incentive Total
At January 1, 2021 14,511,147  4,456  11,404,458  25,920,061 
At March 31, 2021 14,511,147  4,456  11,404,458  25,920,061 

 

  Net income reserves
  Investments reserve  Legal reserve  Fiscal incentive Total
At January 1, 2022 18,359,259  4,456  12,827,925  31,191,640 
At March 31, 2022 18,359,259  4,456  12,827,925  31,191,640 

 

There was no change in net income reserves in the first quarter of 2021 and 2022.

 

(c.1) Investments reserve

From the net income after applicable deductions, there will be a target allocation of no more than 60% of the adjusted net profit to the investment reserve, to be used to support future investments.

(c.2) Legal reserve

From the net income, 5% will be applied before any other allocation to the legal reserve, which cannot exceed 20% of the capital stock. The Company is not required to supplement the legal reserve for the year when the balance of this reserve, plus the amount of the capital reserves, exceeds 30% of the capital stock.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

(c.3) Tax incentives

The Company has tax incentives under certain state and federal industrial development programs in the form of financing, the deferred payment of taxes or partial reductions in the amount due. These programs aim to generate employment, promote regional decentralization, complement and diversify the industrial base of the states. In these states, the grace periods, use and reductions are set out under the tax law.

 

The portion of income for the period related to tax incentives, which will be allocated to the profit reserve at the end of the fiscal year and therefore was not being used as a basis for dividend distribution, was composed of the following:

 

  03/31/2022 03/31/2021
 ICMS (Brazilian state value-added tax) 486,336  398,479 
 Income tax 21,379  43,188 
  507,715  441,667 

 

 

(c.4) Interest on shareholders’ equity/Dividends

Brazilian companies are permitted to distribute the interest attributed to shareholders’ equity calculated based on the long-term interest rate (“TJLP”), with such interest being tax-deductible, in accordance with the applicable law and, when distributed, may be considered part of the minimum mandatory dividends.

As determined by its by-laws, the Company is required to distribute to its shareholders, as a minimum mandatory dividend in respect of each fiscal year ending December 31, an amount of not less than 40% of its net income determined under Brazilian law, adjusted in accordance with the applicable law, unless the payment of such amount would be incompatible with Ambev’s financial situation. The minimum mandatory dividend includes amounts paid as interest on shareholders’ equity.

There was no payment of dividends or interest on shareholders’ equity in the three-month periods ended March 31, 2021 and March 31, 2022.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

(d) Carrying value adjustments

 

  Carrying value adjustments  
  Translation reserves Cash flow hedge Actuarial gains/ (losses) Put option granted on subsidiary Gains/(losses) of non-controlling interest´s share Business combination Accounting adjustments for transactions between shareholders Total
At January 1, 2021 11,076,439  744,441  (1,473,230) (4,783) (73,777) 156,091  (75,414,198) (64,989,017)
Comprehensive income:                
Gains/(losses) on the translation of foreign operations 4,340,712  4,340,712 
Cash flow hedges 655,880  655,880 
Actuarial gains/(losses) (56,230) (56,230)
Total Comprehensive income 4,340,712  655,880  (56,230) 4,940,362 
Gains/(losses) of controlling interest 382  382 
At March 31, 2021 15,417,151  1,400,321  (1,529,460) (4,783) (73,395) 156,091  (75,414,198) (60,048,273)

 

  Carrying value adjustments  
  Translation reserves Cash flow hedge Actuarial gains/ (losses) Put option granted on subsidiary Gains/(losses) of non-controlling interest´s share Business combination Accounting adjustments for transactions between shareholders Total
At January 1, 2022 13,526,157  1,225,253  (1,131,476) (6,666) (121,599) 156,091  (75,426,021) (61,778,261)
Comprehensive income:                
Gains/(losses) on the translation of foreign operations (6,793,284) (6,793,284)
Cash flow hedges (1,117,137) (1,117,137)
Actuarial gains/(losses) 1,050  1,050 
Total Comprehensive income (6,793,284) (1,117,137) 1,050  (7,909,371)
Gains/(losses) of controlling interest (2,259) (2,259)
At March 31, 2022 6,732,873  108,116  (1,130,426) (6,666) (123,858) 156,091  (75,426,021) (69,689,891)

 

 

 

 

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

(d.1) Translation reserves

The translation reserves comprise all foreign currency exchange differences arising from the translation of the financial statements with a functional currency different to the Real.

The translation reserves also comprise the portion of the gain or loss on the foreign currency liabilities and on the derivative financial instruments determined to be effective net investment hedges.

 

(d.2) Cash flow hedge reserves

 

The hedging reserves represent the effective portion of the cumulative net change in the fair value of cash flow hedges to the extent that the hedged risk has not yet impacted profit or loss (for additional information, see Note 23 - Financial instruments and risks).

 

(d.3) Actuarial gains and losses

Actuarial gains and losses include expectations regarding future pension plan obligations. Consequently, the results of actuarial gains and losses are recognized on a timely basis considering the best estimates available to Management. Accordingly, the Company recognizes the results of these estimated actuarial gains and losses, on a monthly basis, based on the expectations presented in the independent actuarial report.

In March, 2021, an actuarial loss of R$56,940 arising from the deficit on the defined benefits plan was fully recorded under actuarial gains and losses as a counterpart to the balance receivable originally recorded. There were no actuarial gains or losses arising from surplus or deficit in 2022.

(d.4) Accounting adjustments for transactions between shareholders

 

As determined by IFRS 10, any difference between the amount paid (fair value) for the acquisition of a non-controlling interest and the carrying amount of such non-controlling interest shall be recognized directly in the controlling shareholders’ equity. The acquisition of the non-controlling interest related to Companhia de Bebidas das Américas (“Former Ambev”), and the abovementioned adjustment was recognized in carrying value adjustments when applicable.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

16.    SEGMENT REPORTING

 

(a)Reportable segments – three-month period ended in:
  Brazil CAC (i) Latin America - South (ii) Canada Consolidated
  03/31/2022 03/31/2021 03/31/2022 03/31/2021 03/31/2022 03/31/2021 03/31/2022 03/31/2021 03/31/2022 03/31/2021
                     
Net sales 9,598,205  8,225,294  2,282,858  2,159,507  4,602,596  4,192,524  1,955,493  2,062,436  18,439,152  16,639,761 
Cost of sales (5,098,063) (3,981,483) (1,165,775) (1,015,443) (2,336,126) (2,103,728) (814,522) (844,676) (9,414,486) (7,945,330)
Gross profit 4,500,142  4,243,811  1,117,083  1,144,064  2,266,470  2,088,796  1,140,971  1,217,760  9,024,666  8,694,431 
Distribution expenses (1,384,892) (1,069,112) (193,618) (209,541) (525,671) (469,921) (424,838) (381,019) (2,529,019) (2,129,593)
Sales and marketing expenses (766,879) (709,406) (143,061) (160,677) (343,880) (325,764) (263,156) (249,193) (1,516,976) (1,445,040)
Administrative expenses (754,896) (789,386) (57,525) (110,359) (198,632) (201,554) (162,383) (132,760) (1,173,436) (1,234,059)
Other operating income/(expenses) 336,793  191,580  24,125  35  22,928  (4,673) 2,876  (9,002) 386,722  177,940 
Exceptional items (13,209) (18,761) (4,364) (16,867) (9,653) (35,302) (495) (27,226) (71,425)
Income from operations 1,917,059  1,848,726  742,640  646,655  1,211,562  1,051,582  293,470  445,291  4,164,731  3,992,254 
Net finance costs (300,644) (390,122) (12,743) (49,693) (266,813) (587,733) (16,513) (36,752) (596,713) (1,064,300)
Share of results of joint ventures (2,392) (1,600) (163) (3,282) 151  (7,664) (2,404) (12,546)
Income before income tax 1,614,023  1,457,004  729,734  593,680  944,749  463,849  277,108  400,875  3,565,614  2,915,408 
Income tax expense 637,668  262,623  (234,645) (190,120) (323,612) (94,865) (116,187) (159,735) (36,776) (182,097)
Net income 2,251,691  1,719,627  495,089  403,560  621,137  368,984  160,921  241,140  3,528,838  2,733,311 
                     
EBITDA (iii) 2,694,120  2,538,626  888,006  819,155  1,494,052  1,335,489  417,112  549,968  5,493,290  5,243,238 
Depreciation. amortization and impairment (779,453) (691,500) (145,529) (175,782) (282,490) (283,907) (123,491) (112,341) (1,330,963) (1,263,530)
Net finance costs (300,644) (390,122) (12,743) (49,693) (266,813) (587,733) (16,513) (36,752) (596,713) (1,064,300)
Income tax expense 637,668  262,623  (234,645) (190,120) (323,612) (94,865) (116,187) (159,735) (36,776) (182,097)
Net income 2,251,691  1,719,627  495,089  403,560  621,137  368,984  160,921  241,140  3,528,838  2,733,311 
                     
EBITDA margin as a % (iii) 28.1% 30.9% 38.9% 37.9% 32.5% 31.9% 21.3% 26.7% 29.8% 31.5%
                     
Acquisition of property, plant and equipment 539,833  963,353  176,408  109,053  134,899  182,311  37,397  72,618  888,537  1,327,335 

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

(continued)

 

  Brazil CAC (i) Latin America - South (ii) Canada Consolidated
  03/31/2022 12/31/2021 03/31/2022 12/31/2021 03/31/2022 12/31/2021 03/31/2022 12/31/2021 03/31/2022 12/31/2021
                     
Segment assets 54,237,671  54,609,401  13,504,759  15,351,934  19,017,807  21,582,950  15,800,085  18,016,562  102,560,322  109,560,847 
Intersegment elimination                 (2,314,387) (2,868,475)
Non-segmented assets                 27,153,985  31,910,111 
Total assets                 127,399,920  138,602,483 
                     
Segment liabilities 24,187,339  27,611,116  4,418,501  5,414,414  6,475,469  7,843,612  5,023,048  6,156,510  40,104,357  47,025,652 
Intersegment elimination                 (2,314,527) (2,869,056)
Non-segmented liabilities                 89,610,090  94,445,887 
Total liabilities                 127,399,920  138,602,483 

 

(i) CAC: includes the Dominican Republic, Panama, Guatemala, Cuba, Barbados, Saint Vincent, Dominica, Nicaragua, Honduras and Antigua.

 

(ii) Latin America - South: includes operations in Argentina, Bolivia, Chile, Paraguay and Uruguay.

 

(iii) From 2021 onwards, the Adjusted EBITDA metric was changed to EBITDA, for presentation purposes, including for comparative purposes.

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

(b)     Additional information - by business unit:

 

  Brazil
  Beer Soft drinks and
Non-alcoholic and
non-carbonated
Total
  03/31/2022 03/31/2021 03/31/2022 03/31/2021 03/31/2022 03/31/2021
             
Net sales 8,100,187  7,124,812  1,498,018  1,100,482  9,598,205  8,225,294 
Cost of sales (4,192,167) (3,401,491) (905,896) (579,992) (5,098,063) (3,981,483)
Gross profit 3,908,020  3,723,321  592,122  520,490  4,500,142  4,243,811 
Distribution expenses (1,142,543) (891,668) (242,349) (177,444) (1,384,892) (1,069,112)
Sales and marketing expenses (708,630) (641,327) (58,249) (68,079) (766,879) (709,406)
Administrative expenses (660,146) (679,847) (94,750) (109,539) (754,896) (789,386)
Other operating income/(expenses) 282,053  152,251  54,740  39,329  336,793  191,580 
Exceptional items (12,641) (18,716) (568) (45) (13,209) (18,761)
Income from operations 1,666,113  1,644,014  250,946  204,712  1,917,059  1,848,726 
Net finance costs (300,644) (390,122) (300,644) (390,122)
Share of results of joint ventures (2,392) (1,600) (2,392) (1,600)
Income before income tax 1,363,077  1,252,292  250,946  204,712  1,614,023  1,457,004 
Income tax expense 637,668  262,623  637,668  262,623 
Net income 2,000,745  1,514,915  250,946  204,712  2,251,691  1,719,627 
             
EBITDA (i) 2,349,714  2,243,592  344,406  295,034  2,694,120  2,538,626 
Depreciation. amortization and impairment (685,993) (601,178) (93,460) (90,322) (779,453) (691,500)
Net finance costs (300,644) (390,122) (300,644) (390,122)
Income tax expense 637,668  262,623  637,668  262,623 
Net income 2,000,745  1,514,915  250,946  204,712  2,251,691  1,719,627 
             
EBITDA margin as a % (i) 29.0% 31.5% 23.0% 26.8% 28.1% 30.9%

 

 (i) From 2021 onwards, the Adjusted EBITDA metric was changed to EBITDA, for presentation purposes, including for comparative purposes.

 

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

17.            NET SALES

 

Reconciliation between gross sales and net sales:

 

  03/31/2022 03/31/2021
Gross sales and/or services 29,307,546  24,544,855 
Excise duty (5,612,468) (5,036,196)
Discounts (5,255,926) (2,868,898)
  18,439,152  16,639,761 

 

18.OTHER OPERATING INCOME/(EXPENSES)

 

  03/31/2022 03/31/2021
Government grants/net present value of long-term fiscal incentives 232,355  171,638 
Extemporaneous credits/(debits) (i) 91,456 
(Additions)/reversals of provisions (12,594) (8,980)
Gains/(losses) on disposals of property, plant and equipment, intangible assets and the operations of associates 33,423  12,667 
Other operating income/(expenses), net 42,082  2,615 
  386,722  177,940 

 

(i) As detailed in Note 25 – Contingencies, the Company has recognized PIS and COFINS credits arising from the exclusion of ICMS from its calculation basis, in the item Other operating income/(expenses).

 

Government grants are not recognized until there is reasonable assurance that the Company will meet the respective conditions and that the grants will be received. Government grants are systematically recognized in income during the periods when the Company recognizes as expenses the related costs that the grants are intended to offset.

 

19.EXCEPTIONAL ITEMS

 

  03/31/2022 03/31/2021
COVID-19 impacts (ii) (10,668) (31,051)
Restructuring (i) (16,558) (39,185)
Effect of application of IAS 29 (hyperinflation) (1,189)
  (27,226) (71,425)

 

(i) The restructuring expenses primarily related to centralized projects and resizing in the Latin America CAC and Brazil.

 

(ii) COVID-19 expenses refer to (a) additional administrative expenses to ensure the safety of our people (increased frequency of cleaning at the Company’s facilities, providing alcohol gel and masks for our employees); (b) donations; (c) Company initiatives providing support for some customer ecosystems, which were necessary due to the COVID-19 pandemic.

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

20.FINANCE EXPENSES AND INCOME

 

(a)Finance expenses

 

  03/31/2022 03/31/2021
Interest expense (397,762) (334,589)
Net interest on pension plans (27,943) (27,827)
Losses on hedging instruments (707,748) (770,864)
Interest on provision for disputes and litigation (39,023) (17,730)
Exchange variations (125,463) (178,421)
Tax on financial transactions (60,688) (11,369)
Bank guarantee expenses (39,155) (30,914)
Other financial results (225,311) (72,681)
  (1,623,093) (1,444,395)

 

Interest expenses are presented net of the effects of interest rate derivative financial instruments which mitigate Ambev’s interest rate risk (Note 23 - Financial instruments and risks). The interest expenses are as follow:

 

  03/31/2022 03/31/2021
Financial instruments measured at amortized cost (110,554) (190,744)
Financial instruments at fair value through profit or loss (287,208) (143,845)
  (397,762) (334,589)

 

(b)Finance income

 

  03/31/2022 03/31/2021
Interest income 397,268  107,353 
Interest and foreign exchange rate on loans to/from related parties 3,322  12,992 
Financial instruments at fair value through profit or loss
Other financial results 294,664  7,957 
  695,254  128,302 
     
Effect of application of IAS 29 (hyperinflation) 331,126  251,793 
  1,026,380  380,095 

 

Interest income arises from the following financial assets:

 

  03/31/2022 03/31/2021
Cash and cash equivalents 77,507  52,008 
Investment securities held for trading 46,390  9,697 
Other receivables 273,371  45,648 
  397,268  107,353 
 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

21.INCOME TAX AND SOCIAL CONTRIBUTION

Income taxes reported in the income statement are analyzed as follow:

  03/31/2022 03/31/2021
Income tax expense - current (262,376) (515,992)
     
Deferred tax expense on temporary differences 221,441  343,539 
Deferred tax on taxes losses carryforwards movements in the current period 4,159  (9,644)
Total deferred tax (expense)/income 225,600  333,895 
     
Total income tax expenses (36,776) (182,097)

 

The reconciliation between the weighted nominal tax rate and the effective tax rate is summarized as follows:

 

  03/31/2022 03/31/2021
Profit before tax 3,565,614  2,915,408 
Adjustment on a taxable basis    
Others non-taxable income (81,135)
Government grants related to sales taxes (486,336) (398,479)
Share of results of joint ventures 2,404  12,546 
Non-deductible expenses 7,404  15,522 
Worldwide Taxation 145,900  (80,802)
  3,153,851  2,464,195 
Aggregated weighted nominal tax rate 28.95% 28.31%
Taxes payable – nominal rate (913,040) (697,582)
Adjustment on tax expense    
Income tax incentives 21,379  43,188 
Deductible interest on shareholders’ equity 746,607  592,679 
Tax savings from goodwill amortization 14,340  19,366 
Withholding income tax 170,625  (288,996)
Recognition/(write-off) of deferred charges on tax losses (4,416) (52,361)
Effect of application of IAS 29 (hyperinflation) (37,501) (14,404)
Others with reduced taxation (34,770) 216,013 
Income tax and social contribution expense (36,776) (182,097)
Effective tax rate 1.03% 6.25%

 

The main events that impacted the effective tax rate for the period were:

 

·Government subsidy for sales taxes: for regional incentives, these are related primarily to local production and, when reinvested, are not subject to income tax and social contribution, which explains the impact on the effective tax rate. The amount above is impacted by fluctuations in the volume, price and any eventual increases in ICMS.

 

·Complement of income tax on foreign subsidiaries due in Brazil: shows the result of the calculation of universal taxation of profits, according to the regulations of Law 12,973/14.

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

·Withholding income tax: the amount is mainly related to dividends already distributed and to be distributed by subsidiaries located outside of Brazil, applicable according to local tax legislation. The amount recognized in 2022 is mainly due to the exchange rate variation of the deferred income tax balances.

 

·Deductible interest on shareholders’ equity: under Brazilian law, companies have an option to remunerate their shareholders through the payment of Interest on Capital (“IOC”), which is deductible for income tax purposes.

 

22.    SHARE-BASED PAYMENTS

 

Currently the Company has two plans of share-based payment programs: (i) Stock Option Plan, approved in the Extraordinary General Meeting of July 30, 2013 (“Stock Option Plan”) and (ii) Share-based Payment Plan approved in the Extraordinary General Meeting of April 29, 2016, as amended in the Extraordinary General Meeting of July 30, 2013 (“Share-Based Plan”). The programs are issued for each plan and there are different stock option and share-based payment programs which allow the employees and senior management of the Company and its subsidiaries to acquire, through the exercise of stock options, or receive shares of the Company.

 

(i) Stock Option Plan

 

There are three models of stock options that may be granted under the Stock Option Plan.

 

1. Under the first model, beneficiaries, in accordance with their internal category, may choose between allocating (a) 30% or 100%, (b) 40% or 100%, and (c) 60% or 100% of the amounts received by them as profit sharing regarding the immediate year to the exercise of stock options, thereby allowing them to acquire the corresponding amount of Ambev shares. Under this model, a substantial part of the shares acquired is to be delivered only within five years from the corresponding stock option grant date. During such five-year period, the beneficiary must remain employed at Ambev or any other company of its group.

 

2. Under the second model, the beneficiary may exercise the stock options granted only after a period of up to five years from the corresponding grant date. Vesting of the stock options granted under the second model is not subject to the Company’s performance measures; however, the right to exercise such options may be forfeited in certain circumstances, including the beneficiary’s resignation or dismissal prior to the stock options’ vesting.

 

3. Under the third model, the beneficiaries, in accordance with their internal category, may choose between allocating (a) 20% or 100%, (b) 30% or 100%, and (c) 50% or 100%, of the amounts received by them as profit sharing regarding the immediate year to the exercise of stock options, thereby allowing them to acquire the corresponding amount of Ambev shares. The totality of the shares acquired is to be delivered to the beneficiary within forty-five days from the corresponding exercising date (which shall not be later than forty-five days from the stock option grant date). The beneficiaries are under a five-year lock-up period.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

For all stock option programs, the fair value of the shares is estimated as at the option grant date, using the “Hull Binomial” pricing model, adjusted to reflect the IFRS 2 requirement that assumptions regarding forfeiture before the end of the vesting period cannot impact the fair value of the option. The fair value of the share options is estimated at the grant date, using an option pricing model. Based on the expected number of options that will be exercised, the fair value of the options granted is recognized as an expense over the vesting period with a corresponding credit to equity. When the options are exercised, the equity is increased by the amount of the proceeds received.

 

(ii) Share-Based Plan

 

In this plan, certain employees and members of the management of the Company or its subsidiaries are eligible to receive shares of the Company, including in the form of ADRs. The shares that are subject to the Share-Based Plan are designated as “restricted shares”.

 

The delivery of restricted shares is made free, and the waiting period may vary between three and five years from the corresponding share-based plan grant date, during which the beneficiary must remain employed at Ambev or any other company of its group.

 

The restricted shares give to participants the right to receive additional shares with the same conditions, such as compensation dividends and Interest on shareholder’s equity paid by the Company during the waiting period. The right to receive restricted and additional shares can be fully or partially lost depending on circumstances, including resignation or resignation during the grace period.

 

Under the Share-Based Plan, the reference price per restricted share is defined on the grant date based on the share price of the trading session on B3 S.A. immediately prior to the granting of the shares and based on the number of grant shares. During the grace period the amount is recorded as expense against equity. The shares are transferred to attendees according to terms and periods by the respective programs.

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

The total number of outstanding options developed was as follows:

 

Thousand options 03/31/2022   12/31/2021
       
Options outstanding at January 113,760    127,265 
Options exercised during the period   (5,247)
Options forfeited during the period (2,003)   (8,258)
Options outstanding at the end of the period 111,757    113,760 

 

The range of exercise prices of the outstanding options is from R$15.95 (R$15.95 in 2021) to R$45.85 (R$45.97 in 2021) and the weighted average remaining contractual life is approximately 6.68 years (6.70 years in 2021).

 

Of the 111,757 thousand outstanding options (113,760 thousand in 2021), 62,164 thousand options were vested in 2022 (59,250 thousand in 2021).

 

The weighted average exercise price of the options is as follows:

 

In R$ per share 03/31/2022   12/31/2021
       
Options outstanding at January 1 19.92    19.81 
Options forfeited during the period 19.44    25.27 
Options exercised during the period   13.16 
Options outstanding at the end of the period 19.92    19.92 
Options exercisable at the end of the period 20.89    21.14 

 

For the period ended in March 31, 2022 there were no options exercised (in December 31, 2021 the weighted average share price as at the exercise date was R$17.87).

 

To settle the exercised stock options, the Company may use treasury shares. The current limit on the authorized capital is considered sufficient to meet the Company’s obligations under all stock option plans if the issue of new shares is required to meet the grants awarded under the Programs.

During the period, the Company did not grant deferred shares under the Stock Option Plan (in 2021 110 thousand deferred shares have been granted, which are valued based on the share price for the trading session immediately prior to the grant, which represented a fair value of R$1,690). Such deferred shares are subject to a grace period of five years from the grant date.

During the period, the Company granted 19,481 thousand restricted shares under the Share-Based Plan (20,629 thousand in 2021), which are valued based on the share price of the trading session immediately prior to the granting of the shares, representing a fair value of approximately R$296,111 in 2022 (R$325,735 in 2021). Such restricted share units are subject to a grace period which can vary from three to five years counted from the grant date.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

Stated below is the total number of shares purchased by or granted to employees, as the case may be, under the Stock Option Plan and Share-Based Plan which will be delivered in the future based on the fulfilment of certain conditions (deferred stock and restricted shares):

 

Deferred shares

 

Thousand deferred shares 03/31/2022   12/31/2021
       
Deferred shares outstanding at January 1 1,168    6,065 
New deferred shares during the period   110 
Deferred shares granted during the period (214)   (4,964)
Deferred shares forfeited during the period (4)   (43)
Deferred shares outstanding at the end of the period 950    1,168 

 

Restricted shares

 

Thousand restricted shares 03/31/2022   12/31/2021
       
Restricted shares outstanding at January 62,545    43,458 
New restricted shares during the period 19,481    20,629 
Restricted shares granted during the period   (22)
Restricted shares forfeited during the period (509)   (1,520)
Restricted shares outstanding at the end of the period 81,517    62,545 

 

Additionally, certain employees and managers of the Company received options to acquire AB InBev shares, the compensation costs of which are recognized in the income statement against equity.

The transactions with share-based payments described above generated an expense of R$78,796 on March 31, 2022 (R$105,960 on March 31, 2021), recorded as administrative expenses.

 

23.FINANCIAL INSTRUMENTS AND RISKS

 

Risk factors

 

The Company is exposed to foreign currency, interest rate, commodity price, liquidity and credit risk in the ordinary course of its business. The Company analyzes each of these risks both individually and on a consolidated basis, to define strategies to manage the economic impact on risk’s performance consistent with its Financial Risk Management Policy (the “Policy”).

 

The Company’s use of derivatives strictly follows the Financial Risk Management Policy approved by the Board of Directors. The Policy is intended to provide guidelines for the management of the financial risks inherent to the capital markets in which Ambev operates. The Policy includes four main aspects: (i) capital structure; financing and liquidity; (ii) transactional risks related to the business; (iii) financial statement translation risk; and (iv) credit risks of financial counterparties.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

The Policy establishes that all the financial assets and liabilities in each country in which Ambev operates must be denominated in their respective local currencies. The Policy also sets out the procedures and controls required to identify, measure and minimize market risks, such as variations in foreign exchange rates, interest rates and commodities (mainly aluminum, wheat, corn and sugar) that may affect Ambev’s revenue, costs and/or investment amounts. The Policy states that all of the known risks (e.g. foreign currency and interest) shall be hedged by contracting derivative financial instruments. Existing risks which are not yet recorded (e.g. future contracts for the purchase of raw materials or property, plant and equipment) shall be mitigated using projections for the period required for the Company to adapt to the new costs scenario, which may vary from ten to fourteen months, also through the use of derivative financial instruments. Most translation risks are not hedged. The exceptions to the policy must be approved by the Operations, Finance and Compensation Committee (COF).

 

Derivative financial instruments

 

The derivative financial instruments authorized under the Financial Risk Management Policy include futures contracts traded on exchanges, full deliverable forwards, non-deliverable forwards, swaps and options. At March 31, 2022, the Company and its subsidiaries had no target forwards, swaps with currency verification, or any other derivative transactions representing a risk level above the nominal value of the contracts. The derivative operations are managed on a consolidated basis and classified based on the strategy according to their purposes, as follows:

 

i) Cash flow hedge derivative instruments - Highly probable forecast transactions contracted to minimize the Company’s exposure to fluctuations in exchange rates and the prices of raw materials, investments, equipment and services to be procured, protected by cash flow hedges that shall occur at various different dates over the next fourteen months. Gains and losses classified as hedging reserves in equity are recognized in the income statement in the period or periods during which the forecast and hedged transaction affects the income statement.

 

ii) Fair value hedge derivative instruments - operations contracted for the purpose of mitigating the Company’s net indebtedness against foreign exchange and interest rate risk. Net cash positions and foreign currency debts are continually assessed to identify new indications of exposure.

 

The results of these operations, measured according to their fair value, are recognized in financial results.

 

iii) Net investment hedge derivative instruments - transactions entered into to minimize the exposure to exchange differences arising from the conversion of net investments in the Company's subsidiaries located abroad for the purpose of translating the account balance.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

In accordance with the hedge accounting, the effective hedge amount is recorded in equity and, in the event of an ineffective portion this result is recorded immediately in finance result during the period ineffectiveness was identified, for cash flow hedge and net investment hedge.

 

The following tables summarize the exposure identified and protected in accordance with the Company’s Risk Policy.

 

Non-derivative financial instruments

 

Put options granted on subsidiaries: the Company constituted a liability related to the acquisition of a non-controlling interest of the operations in the Dominican Republic. This financial instrument is denominated in US Dollars (Tranche A) and Dominican Pesos (Tranche B) and is recorded by an entity, whose functional currency is the Real. The Company assigned this financial instrument as a hedging instrument for a portion of its net assets located in subsidiaries whose functional currency is the US Dollar and the Dominican Peso, in such a manner that the hedge result can be recorded in other comprehensive income of the Group, following the result of the hedged item.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

Transactions protected by derivative financial instruments in accordance with the Financial Risk Management Policy

 

                  03/31/2022
              Fair Value   Gain / (Losses)
Exposure   Risk     Notional   Assets Liabilities   Finance Result Operational Result Equity
                         
Cost     (20,047,668)   20,047,668    623,045  (162,592)   (564,476) 339,502  (1,329,314)
    Commodities (2,781,277)   2,781,277    591,322  (9,523)   (25,586) 291,817  331,487 
    US Dollars (17,080,116)   17,080,116    28,865  (151,045)   (536,355) 39,007  (1,730,526)
    Euros (30,032)   30,032    (1,444)   (350) 274  (1,740)
    Mexican Pesos (156,243)   156,243    2,858  (580)   (2,185) 8,404  71,465 
                         
Fixed Assets     (421,672)   421,672    1,329  (16,251)   (33,373) 8,989  10,748 
    US Dollars (421,672)   421,672    1,329  (16,251)   (33,373) 8,989  10,748 
                         
Expenses     (316,311)   316,311    378  (8,467)   (34,411) 7,244  199,874 
    US Dollars (316,311)   316,311    378  (8,467)   (34,411) 7,244  199,874 
March 31, 2022     (20,785,651)   20,785,651    624,752  (187,310)   (632,260) 355,735  (1,118,692)

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

 

      12/31/2021   03/31/2021
              Fair Value   Gain / (Losses)
Exposure   Risk     Notional   Assets Liabilities   Finance Result Operational Result Equity
                         
Cost     (18,911,847)   18,911,847    597,455  (421,087)   (565,405) 380,447  1,180,937 
    Commodities (3,179,859)   3,179,859    455,294  (41,244)   (40,204) 149,074  157,425 
    US Dollars (15,516,386)   15,516,386    136,243  (378,396)   (524,149) 248,358  1,049,036 
    Euros (31,839)   31,839    (787)   (72) 1,120  (2,170)
    Mexican Pesos (183,763)   183,763    5,918  (660)   (980) (18,105) (23,354)
                         
Fixed Assets     (1,111,350)   1,111,350    1,065  (53,327)   (136,798) 33,714  37,404 
    US Dollars (1,111,350)   1,111,350    1,065  (53,327)   (136,798) 33,714  37,404 
                         
Expenses     (365,752)   365,752    453  (18,132)   (44,404) 13,049  65,247 
    US Dollars (365,752)   365,752    453  (18,132)   (44,404) 13,049  65,247 
                         
Equity Instrument           (55,339)
    Stock Exchange Prices       (55,339)
Total     (20,388,949)   20,388,949    598,973  (492,546)   (801,946) 427,210  1,283,588 

 

 

 

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

I.Market risk

 

a.1) Foreign currency risk

The Company is exposed to foreign currency risk on borrowings, investments, purchases, dividends and/or interest expenses or income where these are denominated in a currency other than the functional currency of the subsidiary. The main derivative financial instruments used to manage foreign currency risk are futures contracts, swaps, options, non-deliverable forwards and full deliverable forwards.

 

a.2) Commodity Risk

A significant portion of the Company’s inputs is made up of commodities, which have historically experienced substantial price fluctuations. The Company therefore uses both fixed price purchasing contracts and derivative financial instruments to minimize its exposure to volatility in the commodity prices of aluminum, sugar, wheat and corn. These derivative financial instruments have been designated as cash flow hedges.

 

a.3) Interest rate risk

The Company applies a dynamic interest rate hedging approach, whereby the target mix between fixed- and floating-rate debt is reviewed periodically. The purpose of the Company’s policy is to achieve an optimal balance between the cost of funding and the volatility of financial results, considering market conditions, as well as the Company’s overall business strategy, which is reviewed periodically.

 

The table below demonstrates the Company’s exposure related to debts, before and after the application of the interest rate hedging strategy, within the limits established by the risk policy. As at March 31, 2022, the Company was not applying hedges to the exposure described below:

 

  03/31/2022
  Risk
  Interest rate Amount in Brazilian Real
Brazilian Reais 7.5% 2,301,351 
Working capital in Argentinean Peso 36.7% 91,463 
Other 10.9% 222,367 
US Dollars 14.0% 11,631 
Canadian Dollars 2.5% 365,213 
Pre-fixed interest rate   2,992,025 
     
     
Brazilian Reais 14.0% 85,782 
Post fixed interest rate   85,782 

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

 

  12/31/2021
  Risk
  Interest rate Amount in Brazilian Real
Brazilian Reais 7.2% 2,343,257 
Working capital in Argentinean Peso 34.7% 30,514 
Other 11.3% 226,037 
US Dollars 13.1% 17,450 
Canadian Dollars 2.5% 430,781 
Pre-fixed interest rate   3,048,039 
     
     
Brazilian Reais 11.6% 82,999 
Post fixed interest rate   82,999 

 

Sensitivity analysis

 

The Company substantially mitigates the risks arising from non-derivative financial assets and liabilities, through the use of derivative financial instruments. In this context, the Company has identified the main risk factors that could generate losses from these derivative financial instruments, and has developed a sensitivity analysis based on three scenarios, which may impact the Company’s future results and/or cash flow, as described below:

 

1 - Probable scenario: Management’s expectations regarding the deterioration of each transaction’s main risk factor. To measure the possible effects on the results of derivative transactions, the Company uses the parametric Value at Risk (“VaR”), a statistical measure developed based on estimates of standard deviation and correlation between the returns of several risk factors. This model provides the loss limit expected for an asset over a certain time period and confidence interval. Under this methodology, we used the potential exposure of each financial instrument, a range of 95% and a horizon of 21 days after March 31, 2022 for the calculation, which are presented in the model.

 

2 - Adverse scenario: 25% deterioration in each transaction’s main risk factor compared to the level observed as at March 31, 2022.

 

3 - Remote scenario: 50% deterioration in each transaction’s main risk factor compared to the level observed as at March 31, 2022.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

 

Transaction Risk Fair Value Probable scenario Adverse scenario Remote scenario
           
Commodities hedge Decrease in commodities price 581,799  479,964  (113,520) (808,839)
Input purchases   (581,799) (479,964) 113,520  808,839 
Foreign exchange hedge Foreign currency decrease (121,346) (329,072) (4,437,944) (8,754,542)
Input purchases   121,346  329,072  4,437,944  8,754,542 
Cost effects  
           
Foreign exchange hedge Foreign currency decrease (14,922) (16,394) (120,340) (225,758)
Capex Purchases   14,922  16,394  120,340  225,758 
Fixed asset effects  
           
Foreign exchange hedge Foreign currency decrease (8,089) (8,811) (87,167) (166,244)
Expenses   8,089  8,811  87,167  166,244 
Expense effects  
   

 

As at March 31, 2022 the Notional and Fair Value amounts per instrument and maturity were as follow:

 

    Notional Value
Exposure Risk 2022 2023 2024 2025 >2025 Total
               
Cost   19,065,964  981,704  20,047,668 
   Commodities 2,553,251  228,026  2,781,277 
   US Dollars 16,371,277  708,839  17,080,116 
   Euros 27,346  2,686  30,032 
   Mexican Pesos 114,090  42,153  156,243 
               
Fixed assets   379,824  41,848  421,672 
   US Dollars 379,824  41,848  421,672 
               
Expenses   296,673  19,638  316,311 
   US Dollars 296,673  19,638  316,311 
    19,742,461  1,043,190  20,785,651 

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

 

    Fair Value
Exposure Risk 2022 2023 2024 2025 >2025 Total
               
Costs   459,545  908  460,453 
  Commodities 566,577  15,222  581,799 
  US Dollars (107,613) (14,567) (122,180)
  Euros (1,434) (10) (1,444)
  Mexican Pesos 2,015  263  2,278 
               
Fixed assets   (13,730) (1,192) (14,922)
  US Dollars (13,730) (1,192) (14,922)
               
Expenses   (7,356) (733) (8,089)
  US Dollars (7,356) (733) (8,089)
    438,459  (1,017) 437,442 

 

II.Credit Risk

 

Concentration of trade receivables credit risk

 

A substantial portion of the Company’s sales is made to distributors, supermarkets and retailers, through a broad distribution network. Credit risk is reduced due to the widespread number of customers and control procedures used to monitor risk. Historically, the Company has not incurred significant losses on receivables from customers.

 

Concentration of counterparty credit risk

 

In order to minimize the credit risk of its investments, the Company has adopted procedures for the allocation of cash and investments, taking into consideration the credit limits and credit analysis of financial institutions, avoiding credit concentration, i.e. the credit risk is monitored and minimized by restricting negotiations to a select group of highly rated counterparties.

 

The selection process for financial institutions authorized to operate as counterparties of the Company is set forth in the Credit Risk Policy, which also establishes exposure limits for each counterparty based on each counterparty's risk rating and capitalization.

 

In order to minimize the credit risk on significant derivative transactions with its counterparties, the Company has adopted bilateral “trigger” clauses. According to these clauses, where the fair value of an operation exceeds a certain percentage of its notional value (generally between 10% and 15%), the debtor must settle the difference in favor of the creditor.

 

Any deposits or cash available must be kept in accounts with top tier banks, or banks with a high credit rating in the respective country. Any position of a short-term nature (less than six months) should be considered as a deposit or cash.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

Counterparty risk must be managed by the Company globally, with product limits established by the treasury area, considering: (i) the counterparty’s credit rating; (ii) the transaction term; (iii) the amount; and (iv) the split between assets and liabilities, in the absence of a clearing clause in derivative contracts.

The counterparty risk is reassessed.

The carrying amounts of cash and cash equivalents, investment securities, trade receivables excluding prepaid expenses, recoverable taxes and derivative financial instruments are disclosed net of provisions for impairment, and represent the maximum exposure to credit risk as at March 31, 2022. As at March 31, 2022, there was no concentration of credit risk on any counterparties in excess of the limits established by the Company’s risk policy.

III.Liquidity Risk

 

Historically, the Company’s primary sources of cash flow have been cash flow from operating activities, the issuance of debt, bank borrowings and equity securities. Ambev’s material cash requirements have included the following:

 

·                  Debt servicing;

·                  Capital expenditure;

·                  Investments in companies;

·Increases in the ownership of Ambev’s subsidiaries or companies in which it holds equity investments;

·                  Share buyback programs; and

·                  Payments of dividends and interest on shareholders’ equity.

 

The Company believes that cash flows from operating activities, cash and cash equivalents and short-term investments, together with derivatives and access to loan facilities are sufficient to finance capital expenditures, financial liabilities and dividend payments in the future.

 

              03/31/2022
  Carrying amount Contractual cash flows Less than 1 year 1-2 years 2-3 years 3-5 years More than
5 years
Trade and other payables (i) 33,193,331  34,492,492  29,765,587  392,844  2,017,951  924,556  1,391,554 
Secured bank loans 247,039  285,213  81,226  52,409  25,670  50,363  75,545 
Unsecured bank loans 84,070  85,782  85,782 
Debentures and bonds (116,554) (116,554)
Other unsecured loans 130,108  286,473  47,638  42,140  32,544  21,459  142,692 
Lease liabilities 2,639,307  2,969,700  760,861  767,069  506,699  611,773  323,298 
  36,293,855  38,003,106  30,741,094  1,254,462  2,582,864  1,491,597  1,933,089 

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

              12/31/2021
  Carrying amount Contractual cash flows Less than 1 year 1-2 years 2-3 years 3-5 years More than
5 years
Trade and other payables (i) 38,976,332  40,186,347  34,690,647  1,279,731  2,248,841  327,195  1,639,933 
Secured bank loans 247,039  328,023  88,883  61,671  26,380  50,363  100,726 
Unsecured bank loans 84,070  84,079  84,079 
Other unsecured loans 130,108  234,594  46,448  48,104  29,095  20,719  90,228 
Lease liabilities 2,639,307  3,070,913  788,514  756,146  550,688  422,406  553,159 
  42,076,856  43,903,956  35,698,571  2,145,652  2,855,004  820,683  2,384,046 

 

(i) Mainly includes amounts related to suppliers, taxes, fees and contributions payables, dividends and interest on equity payable, salaries and charges, put options related to our participation in subsidiaries and other liabilities, except for related parties, with payment term of less than one year.

 

IV.Equity price risk

 

Through the equity swap transactions approved on May 13, 2020 and December 9, 2020 by the Board of Directors of Ambev, the Company, or its subsidiaries, will receive price variations related to its shares traded on the stock exchange, or on its ADRs, thus neutralizing the possible effects of the stock price fluctuations on the share-based payments made by the Company. As these derivative instruments are not eligible for hedge accounting, they were not therefore allocated to any hedging arrangements.

 

On March 31, 2022, the Company does not have equity swap positions (on March 31, 2021 equity swap operations resulted in a loss of R$55,339).

 

V.Capital management

 

The Company is continuously optimizing its capital structure in order to maximize shareholder value while maintaining the desired financial flexibility to execute its strategic projects. Besides the statutory minimum equity funding requirements applicable to the Company’s subsidiaries in different countries, the Company is not subject to any externally imposed capital requirements. When analyzing the capital structure, the Company uses the same debt ratings and capital classifications applied to the interim financial statements.

 

Financial instruments

 

(a) Financial instrument categories

 

The financial instruments held by the Company are managed through operational strategies and internal controls to assure liquidity, profitability, and transaction security. Transactions involving financial instruments are regularly reviewed to assess the effectiveness of the risk exposure that management intends to cover (foreign exchange, and interest rate, among others).

 

The table below shows all the financial instruments recognized in the financial statements, segregated by category:

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

  03/31/2022
  Amortized cost Fair value through profit or loss Total
Financial assets      
Cash and cash equivalents less bank overdrafts 12,796,459  12,796,459 
Trade receivables excluding prepaid expenses 6,703,375  6,703,375 
Investment securities 206,949  1,345,730  1,552,679 
Derivatives hedges 624,752  624,752 
Total 19,706,783  1,970,482  21,677,265 
       
Financial liabilities      
Trade payables 22,513,248  22,513,248 
Put options granted on subsidiaries 2,860,907  2,860,907 
Derivatives hedges 187,310  187,310 
Interest-bearing loans and borrowing 2,986,344  2,986,344 
Other liabilities 1,894,193  1,894,193 
Total 27,393,785  3,048,217  30,442,002 

 

  12/31/2021
  Amortized cost Fair value through profit or loss Total
Financial assets      
Cash and cash equivalents less bank overdrafts 16,597,184  16,597,184 
Trade receivables excluding prepaid expenses 7,084,660  7,084,660 
Investment securities 192,877  1,914,607  2,107,484 
Derivatives hedges 598,973  598,973 
Total 23,874,721  2,513,580  26,388,301 
       
Financial liabilities      
Trade payables 25,694,967  25,694,967 
Put options granted on subsidiaries 3,291,388  3,291,388 
Derivatives hedges 492,546  492,546 
Interest-bearing loans and borrowing 3,100,524  3,100,524 
Other liabilities 2,458,381  2,458,381 
Total 31,253,872  3,783,934  35,037,806 

 

(b) Classification of financial instruments by type of fair value measurement

IFRS 13 defines the fair value as the price that would be received for the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

Also pursuant to IFRS 13, financial instruments measured at fair value shall be classified within the following categories:

 

Level 1 - quoted prices (unadjusted) in active markets available to the entity for identical assets or liabilities as at the valuation date;

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

Level 2 - inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3 -inputs which are not observable for the asset or liability.

 

  03/31/2022   12/31/2021
                   
  Level 1 Level 2 Level 3 Total   Level 1 Level 2 Level 3 Total
Financial assets                  
Financial asset at fair value through profit and loss 1,345,730  1,345,730    1,914,607  1,914,607 
Derivatives - operational hedge 166,494  458,258  624,752    159,081  439,892  598,973 
  1,512,224  458,258  1,970,482    2,073,688  439,892  2,513,580 
Financial liabilities                  
Financial liabilities at fair value through profit and loss 2,860,907  2,860,907    3,291,388  3,291,388 
Derivatives - operational hedge 33,327  153,983  187,310    193,386  299,160  492,546 
  33,327  153,983  2,860,907  3,048,217    193,386  299,160  3,291,388  3,783,934 

 

Reconciliation of changes in the assets categorized at Level 3

 

Financial liabilities at December 31, 2021 3,291,388 
Total gains and losses during the period (430,481)
   Losses/(gains) recognized in net income 29,461 
   Losses/(gains) recognized in equity (459,942)
Financial liabilities at March 31, 2022 2,860,907 

 

(c) Fair value of financial liabilities measured at amortized cost

 

The Company’s liabilities, interest-bearing loans and borrowing, trade payables excluding tax payables, are recorded at amortized cost based on the effective rate method, plus indexation and foreign exchange gains/losses, based on the closing indices for each exercise.

The financial instruments recorded at amortized cost are similar to the fair value and are not sufficiently material to require disclosure.

 

(d) Fair value of liabilities measured through profit or loss

 

As part of the negotiations regarding the acquisition of the shares of Tenedora, the Company signed the second amendment to the Shareholders’ Agreement extending the partnership between the Company and ELJ. ELJ is currently the owner of 15% of the shares of Tenedora, and its put options are now divided into two tranches: (i) Tranche A, corresponding to 12.11% of the shares, exercisable in 2023 and 2024; and (ii) Tranche B, corresponding to 2.89% of the shares, exercisable from 2026. The Company, on the other hand, has a call option over the Tranche A shares, exercisable from 2021, and Tranche B shares, exercisable from 2029, whereas until March 31, 2022, no options were exercised. On March 31, 2022, the sum of the two ELJ tranches is R$2,854,324 (R$3,284,805 on December 31, 2021).

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

The fair value of Tranche A is calculated considering the interest under the contract, plus foreign exchange variations, less the dividends paid between the date of signature of the amendment and the exercise of the option.

 

The fair value of Tranche B is calculated based on the EBITDA multiple defined in the contract, less the net debt, brought to its present value, calculated using standard valuation techniques (the present value of the principal amount and future interest, discounted by the local currency’s weighted average cost of capital rate as at the date of the calculation). The criteria used are based on market information from reliable sources and are categorized as “Level 3”.

 

Calculation of the fair value of derivatives

 

The Company measures derivative financial instruments by calculating their fair value, using market curves that impact the value of the instrument as at the computation date. In the case of swaps, the asset and the liability positions are estimated independently and brought to their fair value, equivalent to the difference between the results of the asset and liability amounts, which generates the swap’s market value. For traded derivative financial instruments, the fair value is calculated based on the exchange-listed price.

 

Margins pledged as guarantees

 

In order to comply with the guarantee requirements regarding derivative exchanges and/or counterparties to certain operations with derivative financial instruments, as at March 31, 2022 the Company held R$1,052,972 in highly liquid financial investments or in cash, classified as cash and cash equivalents and investment securities (R$1,152,769 as at December 31, 2021).

 

Offsetting of financial assets and liabilities

 

For financial assets and liabilities subject to settlement agreements on a net basis or similar agreements, each agreement between the Company and the counterparty allows this type of settlement when both parties opt for this. In the absence of such a decision, the assets and liabilities will be settled at their gross amounts, but each party shall have the option to settle on a net basis, in case of a default by the counterparty.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

24.    COLLATERAL AND CONTRACTUAL COMMITMENTS WITH SUPPLIERS, ADVANCES FROM CUSTOMERS AND OTHERS

 

  03/31/2022 12/31/2021
     
Collateral given for the Company’s own liabilities 739,788  788,709 
Other commitments 1,435,415  1,718,968 
  2,175,203  2,507,677 
     
Commitments to suppliers 45,866,280  51,561,982 
  45,866,280  51,561,982 

 

The collateral provided for liabilities totaled approximately R$2,175,203 as at March 31, 2022 (R$2,507,677 as at December 31, 2021), including R$688,752 (R$682,636 as at December 31, 2021) of cash guarantees. The deposits in cash used as guarantees are presented as part of other assets. To provide the guarantees required for derivatives exchanges and/or counterparties contracted in certain derivative financial instrument transactions, as at March 31, 2022, Ambev maintained R$1,052,972 (R$1,152,769 as at December 31, 2021) in highly liquid financial investments or in cash, classified as cash and cash equivalents and investment securities (Note 23 - Financial instruments and risks).

Most of the balance relates to commitments to suppliers of packaging.

Future contractual commitments as at March 31, 2022 and December 31, 2021 are as follow:

 

  03/31/2022 12/31/2021
     
Less than 1 year 10,500,213  11,559,858 
Between 1 and 2 years 9,494,831  9,982,233 
More than 2 years 25,871,236  30,019,891 
  45,866,280  51,561,982 

 

25.CONTINGENCIES

 

The Company has contingent liabilities related to lawsuits arising in the normal course of its business. Due to their nature, such legal proceedings involve certain uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions, and therefore the Company’s management cannot estimate the likely timing of the resolution of these matters at this stage.

 

Contingent liabilities with a probable outcome are fully recorded as liabilities (Note 14 - Provisions).

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

The Company and its subsidiaries have lawsuits related mainly to tax for which the likelihood of loss is classified as possible by management, and for which there are no provisions, as the composition and estimates of these amounts are as follow:

 

  03/31/2022 12/31/2021
     
Income tax and social contribution 55,034,341  54,258,733 
Value-added and excise taxes 24,537,488  23,912,359 
PIS and COFINS 3,014,826  2,667,560 
Others 1,667,963  1,606,253 
  84,254,618  82,444,905 

 

Principal lawsuits with a likelihood of possible loss

 

Except for monetary inflation, there were no relevant changes in the main cases with possible chances of loss when compared to the period ended December 31, 2021.

 

Contingent assets

 

In 2017, the STF decided for, in the judgment of RE No. 574,706/PR, with binding effects, the unconstitutionality of the inclusion of ICMS in the taxable basis of PIS and COFINS. Such decision was ratified by the STF in May 2021, within the judgement of the amendment presented by the General Attorney's Office (PGFN), when the Court confirmed that the ICMS to be excluded from the PIS and COFINS taxable basis is that declared in the invoice and determined that the decision should produce effects only as of March 15, 2017 (date on which RE 574,706/PR was ruled), except for taxpayers who had judicial and administrative claims filed until that date (which is the case for the Company and its subsidiaries).

 

The Company and its subsidiaries have several lawsuits related to this matter, some with final and unappealable favorable decisions. As the federal tax regime applicable to the soft drinks and beer sector has changed over time, the Company and its subsidiaries have lawsuits which refer to three different periods: (i) 1990 to 2009, (ii) 2009 to 2015 (period in which the “REFRI Taxation Model” was in force - special soft drinks and beer regime, provided for Article 58-J of Law No. 10,833 of 2003) and (iii) from 2015 onwards (also known as “New Model Taxation”).

 

From 2018 to 2022, the Company and its subsidiaries recognized, in accordance with IAS 37, recoverable tax credits related to this matter in the total amount of R$7.6 billion, of which (i) R$0.7 billion is related to the period from 1990 to 2009 and R$2.4 billion refers to New Model Taxation, being R$1.7 billion related to the period from 05/2015 to 02/2017 and R$0.7 related to the period from 03/2017 to 12/2018 when the Company and its subsidiaries implemented the judicial decisions authorizing the exclusion of the ICMS from the PIS and COFINS taxable basis in its regular transactions and which right of recovery is protected considering the decision rendered by the STF in the context of the judgment of RE 574.706/PR and (ii) R$4.45 billion is related to periods from 2009 to 2015, during which the REFRI Taxation Model was in effect. Part of these amounts has already been offset by the Company and its subsidiaries, according to the final and unappealable decision of the respective judicial lawsuit and the necessary administrative procedures. Amounts yet to be offset remain registered in the asset account (see Note 8 – Recoverable Taxes).

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

The accounting recognition of the amounts mentioned above occurred as a result of (i) the realization of the gain being virtually certain according to the decision provided by the STF in RE 574,706/PR and the specific circumstances of each case; and (ii) the fact that the amount could be estimated with sufficient reliability, by collecting the respective documents and quantifying the related amount. As to the tax credit related to the period in which the REFRI was in force, the amount could be estimated with sufficient reliability after several analyses made (with the assistance of our external consultants) that allowed (i) the identification of the total ICMS included per liter in the retail selling prices that were verified by the Federal Government at the time and that had an impact on the reference prices used as the basis for determination of the PIS and COFINS; and (ii) the calculation of the exclusion of such total ICMS from the taxable basis of PIS and COFINS in the transactions carried out by the Company and its subsidiaries.

 

In addition, with respect to transactions realized after the implementation of the individual judicial decisions authorizing the exclusion of the ICMS from the PIS and COFINS taxable basis, the Company and its subsidiaries had a positive impact of R$4.1 billion, net of the amounts mentioned above, which represented a reduction in the PIS and COFINS expense.

 

For additional matters related to the New Model Taxation, the Company estimates that the contingent asset corresponds to R$0.2 billion, which will be recognized once the realization of the gain is virtually certain given the specific circumstances of the case and upon confirmation of the estimated values with sufficient reliability.

 

26.    RELATED PARTIES

 

Policy and practices regarding the realization of transactions with related parties

 

The Company adopts the corporate governance practices recommended and/or required by the applicable laws.

 

Under the Company’s by-laws, the Board of Directors is responsible for approving any transactions or agreements between the Company and/or any of its subsidiaries (except for full subsidiaries), its directors and/or shareholders (including direct or indirect shareholders of the Company). The Antitrust Compliance and Related Parties Committee of the Company is required to advise the Board of Directors of the Company on all transactions with related parties.

 

Management is prohibited from interfering in any transaction in which a conflict of interest exists, even in theory, with the Company’s interests. Management also are not permitted to interfere in decisions of any other members of management, and the Minutes of Meeting of the Board are required to document any decision to abstain from the respective deliberations.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

The Company’s guidelines on related parties require it to follow reasonable or commutative terms, similar to those prevailing in the market, or under which the Company would contract similar transactions with third parties. These related parties transactions are clearly disclosed in the interim financial statements as formalized in the written contracts.

 

Transactions with management members

 

In addition to short-term benefits (primarily salaries), management members are entitled to participate in the Stock Option Plan and Share-Based Payments Plan (Note 22 - Share-based payments).

 

Total expenses related to the Company’s management members are as follow:

  03/31/2022 03/31/2021
     
Short-term benefits (i) 16,086  28,828 
Share-based payments (ii) 11,708  10,765 
Total key Management remuneration 27,794  39,593 

 

(i) These mainly correspond to management’s salaries and profit sharing (including performance bonuses).

 

(ii) These correspond to the compensation cost of share options and restricted stocks granted to management. These amounts exclude remuneration paid to members of the Fiscal Council.

 

Excluding the abovementioned plan (Note 22 - Share-based payments), the Company no longer has any types of transaction with the Management members or pending balances receivable or payable in its balance sheet.

Transactions with the Company's shareholders:

 

a) Medical, dental and other benefits

Fundação Zerrenner is one of Ambev’s shareholders, and at March 31, 2022 held 10.2% of its total share capital. Fundação Zerrenner is also an independent legal entity whose main goal is to provide Ambev’s employees, both active and retired, with health care and dental assistance, technical and higher education courses, and facilities for assisting elderly people, either directly or through financial assistance agreements with other entities. As at March 31, 2022 and December 31, 2021, actuarial obligations related to the benefits provided directly by Fundação Zerrenner were fully funded by plan assets, held for that purpose, which significantly exceeded the liabilities at these dates. Ambev recognizes the assets (prepaid expenses) of this plan to the extent of the economic benefits available to the Company, arising from reimbursements or from reductions in future contributions.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

The expenses incurred by Fundação Zerrenner with third parties, for providing these benefits totaled R$73,726 (R$69,777 as at March 31, 2021), of which R$64,646 and R$9,080 were related to active employees and retirees respectively (R$62,224 and R$7,553 as at March 31, 2021 related to active employees and retirees respectively).

b) Leasing

Ambev, through its subsidiary BSA (labeling), has an asset leasing agreement with Fundação Zerrenner, for R$23,964, for four years and with monthly payments until December 31, 2022.

c) Leasing - Ambev head office

Ambev has a leasing agreement for two sets of commercial premises with Fundação Zerrenner, for R$5,277, for five years and with monthly payments until December 31, 2025.

d) Licensing agreement

 

The Company has a licensing agreement with Anheuser-Busch, Inc. to produce, bottle, sell and distribute Budweiser products in Brazil, Canada and Argentina, and sales and distribution agreements for Budweiser products in Guatemala, the Dominican Republic, Paraguay, El Salvador, Nicaragua, Uruguay, Chile, Panama, Costa Rica and Puerto Rico. In addition, the Company produces and distributes Stella Artois products under a license to AB InBev in Brazil and Canada and, through a license granted to AB InBev, also distributes Brahma products in the United States and several other countries such as the United Kingdom, Spain, Sweden, Finland and Greece. The amount recorded in relation to this agreement was R$3,195 as at March 31, 2022 (R$326 as at March 31, 2021) and R$164,041 (R$163,248 as at March 31, 2022) as licensing income and expenses, respectively.

 

Ambev has licensing agreements with the Group Modelo, subsidiaries of AB InBev, to import, promote and sell Corona products (Corona Extra, Corona Light, Coronita, Pacifico and Modelo) in Latin America and Canada.

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

Transactions with related parties

 

  03/31/2022
Current Trade receivables (i) Other trade receivables (i) Trade payables (i) Dividends receivables
AB Africa 4,087 
AB InBev 118,172  (197,352)
AB Package (110,269)
AB Services 22,803  (3,113)
AB USA 45,801  6,355  (280,060)
Bavaria 9,006  (13,962)
Cervecería Modelo 13,279  (403,305)
Cervecerías Peruanas 316  (7,838)
Inbev 656  21,968  (52,526)
Panama Holding 3,473  1,364 
Other 10,825  907  (39,161)
  228,418  29,230  (1,107,586) 1,364 

 

(i) The amount represents trading operations (purchase and sale) and reimbursements between the companies of the group.

 

  12/31/2021
Current Trade receivables (i) Other trade receivables (i) Trade payables (i) Dividends receivables
AB Africa 5,282 
AB InBev 45,423  (167,018)
AB Package (63,117)
AB Services 32,698  (3,024)
AB USA 34,498  11,454  (330,678)
Bavaria 3,604  (11,046)
Cervecería Modelo 6,133  (548,431)
Cervecerías Peruanas 3,362  (16,594)
Inbev 813  26,412  (26,448)
Panama Holding 4,643  1,512 
Other 16,627  1,093  (43,867)
  153,083  38,959  (1,210,223) 1,512 

 

(i) The amount represents trading operations (purchase and sale) and reimbursements between the companies of the group.

 

  03/31/2022 12/31/2021
Non-current Trade payables Trade payables
ITW International (343,176) (407,916)
  (343,176) (407,916)
 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

The tables below represent transactions with related parties, recognized in the income statement:

 

  03/31/2022
Company Sales and other Service fees / Reimbursement of expenses and other receivables   Product purchases and other Service fees / reimbursement of expenses and other payables Net finance cost
AB InBev   (42,554)
AB Package   (86,608)
AB USA 6,453    (257,936) (816)
Ambev Peru 331   
Bavaria 50,109    (14,790)
Cervecería Modelo 630    (398,328)
Cervecerías Peruanas   (7,607)
GCC India   (1,990)
Inbev   (68,066)
ITW International   3,322 
Other 849  3,259    (37,326)
  58,372  3,259    (913,215) (2,806) 3,322 

 

  03/31/2021
Company Sales and other Service fees / Reimbursement of expenses and other receivables   Product purchases and other Service fees / reimbursement of expenses and other payables Net finance cost
AB InBev   (32,193)
AB Package   (72,608)
AB Procurement   (16,104)
AB USA 5,205    (294,923) (825)
Ambev Peru 1,368   
Bavaria 1,894    (19,558)
Cervecería Modelo   (436,422)
Cervecerías Peruanas 3,539    (9,605)
GCC India   (1,896)
Inbev   (32,903)
ITW International   12,992 
Other 4,344  38    (28,302)
  16,350  38    (926,514) (18,825) 12,992 

 

 

AMBEV S.A.

 

Notes to the interim consolidated financial statements

For the period ended March 31, 2022

All amounts in thousands of Brazilian Reais unless otherwise stated

 

List of companies included in the tables above:

 

AB InBev Procurement GmbH (“AB Procurement”)
Ambrew S.A.R.L. (“Ambrew”)
Anheuser-Busch Inbev Africa (Pty) Ltd. (“AB Africa”)
Anheuser-Busch InBev N.V. (“AB InBev”)
Anheuser-Busch Inbev Services LLC (“AB Services”)
Anheuser-Busch Inbev USA LLC (“AB USA”)
Anheuser-Busch Packaging Group Inc. (“AB Package”)
Bavaria S.A. (“Bavaria”)
Cervecería Modelo de Mexico S. de R.L. de C.V. (“Cervecería Modelo”)
Cerveceria Nacional S de RL (“Panamá Holding”)
Compañia Cervecera Ambev Peru S.A.C. (“Ambev Peru”)
GCC Services India Private Ltd. (“GCC India”)
Inbev Belgium N.V. (“Inbev”)
Interbrew International B.V. (“ITW International”)
Oriental Brewery Co. Ltd. (“Oriental Brewery”)
Unión de Cervecerias Peruanas Backus Y Johnston S.A.A. (“Cervecerías Peruanas”)

 

 

 

 
 
 
 

SIGNATURE



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: May 17, 2022

     
  AMBEV S.A.
     
  By:  /s/ Lucas Machado Lira
 

Lucas Machado Lira

Chief Financial and Investor Relations Officer


Ambev (NYSE:ABEV)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Ambev Charts.
Ambev (NYSE:ABEV)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Ambev Charts.